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AUTHOR INTRODUCTION 
Karsten Fleischer Rex, born 1979, Maniitsoq, Greenland. Master in Medicine 2009 
from Aarhus University, Denmark.  Completed a 5-year specialist training in 
Greenland in General Medicine by 2017. Staff specialist at the Department of 
Internal Medicine, Queen Ingrid’s Hospital, Nuuk, Greenland 2017. Part time Ph.D. 
student 2014-2019 from the University of Aalborg and the University of Greenland 
on chronic hepatitis B infection among Greenlanders. 
The PhD included HBV data-collection on Greenlanders in Denmark and a 10-year 
follow-up data collection on a 1998 Greenlandic cohort in Greenland using all 
available registries and electronic medical records. In addition, I have engaged in a 
number of activities in relation to science in the Arctic. These include a presentation 
on hepatitis B, D and C on Greenlandic Inuit migrated to Denmark at the 15th 
International Congress on Circumpolar Health (ICCH15). Speaker at the NunaMed 
2013 Conference on ”HBV and Alcohol” and “weight among children in Greenland at 
school-entry” in Nuuk, Greenland. Speaker on “HBV in Greenland” at the “World 
Indigenous Peoples’ Conference on Viral Hepatitis” in Australia in 2014. Speak at the 
Greenland Medical Society, Copenhagen Denmark meeting on “Chronic hepatitis B 
and monitoring in Greenland” in 2014 in Copenhagen, Denmark and attended 
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meeting in 2015. Speaker on ‘Hepatitis’ at the Medical staff forum, DIH, Nuuk 2016 
and speaker on ‘Ethical Principles in HBV research’ at the PhD summer school in Nuuk 
in 2016. Chairman and speaker on the ‘HAV, HBV and the HDV’-session on ‘the HBV 
and HDV-outbreak in Itilleq Greenland on a clinical view, containment and 
vaccination strategies’, at NunaMed 2016. Teaching staff at the Sisimiut Health Care 
Centre, Greenland 2017 and staff at the Internal Medical Department Nuuk 2018 on 
Hepatitis B diagnostics and occult hepatitis B infections. Global Health Course 
Speaker on ‘Hepatitis B & D’ and ‘working as a M.D. in Greenland’, August 30th, Nuuk 
Greenland 2017. Also, teaching staff at Queen Ingrid’s Health Care Centre (DIS Nuuk) 
on HBV and overall survival based on PhD study findings 2018. Presenting PhD 
findings on HBV and overall survival June 2018 at PhD course in Nuuk and later 
presenting findings at the ICCH17 also being ICCH Chairman on the ‘HIV, HPV and 
viral hepatitis’ session. Furthermore, keynote speaker on ‘Being indigenous and 
returning to serve a native population’ at the ICCH17. In addition, it was an honor to 
receive the Jens Peder Hart Hansen Award at the ICCH in 2015. 
HBV related activities have been an integral part of my clinical work. This include 
updating the Clinical Guideline for HBV vaccination among newborns in DIH Nuuk, 
treatment and blood sampling guidelines for pregnant and adult patients in 
Greenland on HIV, HBV and HDV infections. Visiting hyper-endemic HBV and HDV 
village Itilleq in Greenland for blood sampling, vaccination, management, treatment 
and future monitoring capabilities on August 19-20th, 2015 and September 21st, 
2016. Monitoring of HBV and HDV in a local municipality “Qeqqa Kommunia” in 
Sisimiut Greenland and surrounding villages by paraclinical assessment, 2016-17. 
Working in the weekly infectious disease outpatient clinic concerning tuberculosis, 
HIV and hepatitis at Queen Ingrids Hospital, Internal Medical Department, Nuuk 
from 2017. Being a consultant at the Internal Medical Department in Nuuk 
concerning hepatitis- and HIV-related questions among others from all of Greenland.  
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Itilleq settlement in Greenland 
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ABSTRACT (SUMMARY IN ENGLISH) 
Background 
HBV-infection is a global health problem and may cause end-stage liver disease 
including liver cirrhosis and hepatocellular carcinoma (HCC). Due to the poor 
prognosis, HCC is the third most common cause of cancer related death. HBV-
infection is known to be endemic among the arctic Inuit and in regions of Greenland 
prevalence of HBV has been found to be as high as 29%. The overall low incidence of 
HCC in chronically HBV-infected Greenlanders has suggested a more benign course 
of infection in Greenland than in other parts of the world.  
Aim 
The overall aim of this PhD study was to elucidate disease burden of HBV-infections in 
the Greenlandic population. This assessed by comparing Greenlanders with frequent 
HBV-infections to migrated Inuit Greenlanders in a subsequent cross-sectional study in 
Denmark in 2006. In addition, assessing overall survival and disease burden over a 
course of ten years. Secondarily, we wanted to cultivate a foundation for a future 
monitoring program and containment of HBV-infections in Greenland.  
Methods 
We performed an interview on dietary habits, smoking habits and on alcohol use 
through two population-based studies. Clinical assessment on body build 
parameters, blood sampling on liver function tests and markers of HBV-infection was 
investigated. All available registers and electronic medical records were reviewed for 
a HBV-related 10-year follow up on participants in Greenland. Secondarily, working 
in different parts of Greenland with hepatitis patients during the course of the 5-year 
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part time PhD made a foundation on an idea for a future monitoring program and 
containment of HBV-infections in Greenland.  
Results 
A total of 671 Greenlanders in Greenland and Inuit in Denmark were surveyed. 
Prevalences of serological markers of hepatitis B, D and C virus infection showed no 
difference between Greenlanders living in Greenland and Greenlanders migrated to 
Denmark. Our studies did not show evidence of serological or clinical signs of disease 
when comparing HBV-infected to non-infected.  
Inuit had lower alcohol use. In general, Greenland Inuit had higher levels of AST, GGT 
and ALK than non-Inuit. The association between AST and alcohol intake was 
modified by ethnic origin with higher levels of AST among Inuit than on non-Inuit on 
the increase of alcohol use. 
 In contrast to Greenland intravenous drug use can occur in Denmark. This may 
introduce a new way of transmission of disease among Greenlanders.  
Survival analyses show a markedly decrease in lifespan among the infected on a 10-
year period of follow-up. 
Conclusion 
We document that HBV-, HDV- and HCV-infection marker proportions in Denmark 
Inuit mirror proportions reported in Greenland. This imply infection on Greenland 
Inuit before migration on an earlier age from a high endemic area to a low endemic 
area. We find evidence of the possibility of HBV-infections to be transmitted in 
adulthood in addition to infection transmission earlier in life in Greenland. 
Intravenous drug use has been considered non-existing among Inuit in Greenland. 
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Our study show that intravenous drug use can be introduced to Greenlanders on 
migration and the possibility of infection by this route therefore exists in the studied 
population. We suggest ethnic differences in liver biochemistry. There was no 
evidence of a HBV-related disease judging on clinical manifestation or on LFTs.  The 
profound reduced lifespan among the HBV-infected could not be directly ascertained 
to severe HBV-related diseases when looking into data registries and EMRs. We 
consider that HBV-infection in the Greenland Inuit population may not be the benign 
disease that has been previously suggested.  
Public health implications 
In a clinical setting, matters on HBV-infections have lost their momentum in 
Greenland with the risk of undiagnosed HBV-related deaths. HBsAg-positivity in the 
population still occur. The development in Greenland in general leaves great 
enhancement opportunities for HBV-monitoring. A feasible way of getting a clinical 
database on HBV-infected and HBV-exposed in Greenland is to gather all available 
data on infection status found in clinical and in research settings. Management 
should also rely on diagnosis by a yearly extraction of HBV-serology from the 
nationwide laboratory findings. Monitoring HBV-infections in Greenland will in turn 
give a better understanding of the disease, to insure treatment on indication and to 
reduce the risk of cirrhosis, end stage liver disease and HCC. HBV-vaccines to all non-
exposed Greenlanders and to immigrants will be an effective way to lessen HBV-
related problems in the future.  
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DANSK RESUMÉ (SUMMARY IN DANISH) 
Baggrund 
Hepatitis B-infektion (HBV-infektion) er et globalt sundhedsproblem, som kan føre 
til følgesygdomme som skrumpelever og hepatocellulært karcinom (HCC). Grundet 
dårlig prognose er leverkræft (hepatocellulært karcinom [HCC]) den tredje mest 
almindelige årsag til kræft-relateret død. HBV-infektioner er endemiske i 
Inuitbefolkninger i Arktis og i områder i Grønland er prævalencen fundet så høj som 
29%. Grundet den lave forekomst af HCC blandt kronisk inficerede Hepatitis B bærer 
i Grønland har man formodet et mere benignt forløb her end i andre steder i verden.  
Formål 
Det overordnede mål for denne PhD-afhandling er at belyse sygdomsbyrden ved 
HBV-infektion i den grønlandsk befolkning. Dette vurderet ved at sammenligne 
grønlændere med hyppig forekomst af HBV-infektioner i Grønland med grønlændere 
i Danmark. Derudover at vurdere overlevelse og sygdomsbyrde over en tiårs periode. 
Sekundært at kultivere et fundament for et muligt monitoreringsprogram og 
inddæmning af HBV-infektioner i Grønland. 
Metoder  
Gennem to populationsbaserede studier blev der udført et interview med fokus på 
kostvaner, rygevaner og alkoholforbrug. Mål for kropsbygning og blodprøver med 
undersøgelse af levertal og HBV-infektionsmarkører blev udført. Alle disponible 
registre og elektroniske patient journaler blev gennemgået med henblik på en HBV-
relateret tiårs opfølgning på deltagere i Grønland. Et grundlag for udarbejdning af et 
muligt fremtidigt program for monitorering og inddæmning af leverbetændelse i 
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Grønland baseredes på arbejde i Grønland med blandt andet 
leverbetændelsespatienter i perioden for den 5-årige deltids-PhD-ansættelse. 
Resultater 
I alt blev 671 grønlændere i Grønland og Inuit i Danmark undersøgt. Prævalencerne 
af serologiske markører for leverbetændelse type B, D og C var uden forskelle mellem 
grønlændere i Grønland og grønlændere som var immigreret til Danmark. Vores 
studie viste heller ingen evidens for forskelle i levertal eller kliniske tegn til sygdom 
når man sammenlignede HBV-smittede med ikke-smittede. 
Inuit havde lavere alkoholforbrug. Inuit havde generelt højere værdier af AST, GGT 
og ALK end ikke-Inuit. Associationen mellem AST og alkoholindtagelse  modificeredes 
af etnisk baggrund med højere værdier af AST hos Inuit end ikke-Inuit ved øget 
alkoholforbrug.  
I modsætning til i Grønland kan intravenøs stofmisbrug forekomme i Danmark. Dette 
kan introducere en ny måde for mulig smittespredning blandt grønlændere. 
Overlevelsesanalyserne viser en markant nedsat levetid for de HBV-inficerede i 
forhold til ikke-inficerede over en 10-års periode. 
Konklusion 
Vi dokumenterer at proportionerne på HBV-, HDV- og HCV-infektionsmarkører 
blandt grønlændere i Danmark ligner proportionerne i Grønland. Dette formås at 
kunne skyldes infektion før immigration fra et høj-endemisk HBV-område til et lav-
endemisk område. Vi finder evidens for at HBV-smitte i Grønland kan forekomme i 
voksenalderen ud over smitte tidligere i livet. Intravenøs stofmisbrug er vurderet 
som ikkeeksisterende blandt Inuit i Grønland.  
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Vores undersøgelse viser at intravenøs stofmisbrug kan blive introduceret til den 
grønlandske befolkning ved migration og der foreligger herved en ny måde hvorpå 
smittespredning kan foregå.  
Vi antyder at der kan foreligge forskelle i leverbiokemi på baggrund af etnicitet. Der 
var ingen evidens for HBV-relateret sygdom vurderet ud fra kliniske manifestationer 
og levertal.  
Den markant reducerede levetid for de HBV-inficerede kunne ikke direkte relateres 
til HBV-følgesygdomme når man så på dataregistre og elektroniske patientjournaler. 
Vi overvejer dog at HBV-infektion i Grønland måske ikke er den benigne sygdom, som 
før antaget.  
Folkesundhedsmæssige implikationer 
I den kliniske hverdag har HBV-infektioner tabt fokus i Grønland med risiko for 
underdiagnosticerede HBV-relaterede dødsfald. HBV-smitte forekommer fortsat.  
Udviklingen generelt i Grønland giver gode muligheder for forbedringer i HBV-
monitorering. En mulighed for at få en database over HBV-inficerede og HBV-
eksponerede i Grønland vil være at indsamle al tilgængelig data på HBV-målinger 
blandt grønlændere foretaget i den kliniske hverdag samt fra 
forskningssammenhænge. Registrering og styring bør også bygge på diagnose ved 
udtræk af HBV-serologi fra det landsdækkende laboratorie-register. Monitorering af 
HBV-infektioner i Grønland vil give bedre forståelse for sygdommen og forsikre 
behandling på indikation samt reducere risikoen for følgesygdomme heraf.  
HBV-vaccine til alle ueksponerede grønlændere og immigranter vil være en effektiv 
måde hvorpå HBV-relaterede problemer kan mindskes i fremtiden. 
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Kalaallisut eqikkarneqarnera (Summary in Greenlandic) 
Tunuliaqut  
Tunillannartumik tingukkut aseruuttoorneq type B (HBV) nunarsuatsinni nappaatit 
kingunerisinnaasai ukuusinnaasut pillugit peqqinnissamut aarlerinarsinnaavoq; 
tinguup eqinnera imaluunniit tingukkut kræfteqalertarneq (HCC). Tingukkut 
kræfteqarneq (HCC) ajorunnaarsaruminnaannera pillugu kræftimik 
toqussutaasartoq pingajorivaat. Innuttaasuni nunani issittuni Kalaallit Nunatsinnilu 
najugalinni annerpaamik 29%-iisa tuniluuttumik tingulluummik type B (HBV) 
tunillatsinnikuupput. Kalaallit Nunatsinni tingullunnermik ataavartumik type B-mik 
tunillatinnikut akornanni tingumikkut kræfteqalersartut (HCC) 
naammattuugassaavallaanngillat. Tamatumunnga pissutaasorineqarpoq 
tingullulersimasut oqinnerusumik atugassaqarsimanerat. 
Siunertaq  
Ilisimatuutut allaatigisami pingaarnertut siunertaavoq kalaallini Kalaallit Nunaanni 
najugaqartuni aammalu kalaallini Danmarkimi najugaqartuni tingullunnerup 
atugaanera erseqqissassallugu. 
Misissuinermi tunngaviusut ilagaat Kalaallit Nunatsinni tingullunnermik 
tunillatinnikut nakkutilliiveqalernissaat. 
Periaaseq  
Misissuinerni marluusuni peqataasut apersorneqarneranni nerisaqarneq, 
tujortarneq imigassartortarnerlu qitiutinneqarput. Peqataasut timip 
sananeqaataanik misissorneqarput tingullunnermullu aaversinnermi 
misissorneqarlutik. Ukiut qulit qaangiunnerini peqataasut Kalaallit Nunatsinni 
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najugaqartut malittarineqarsinnaaniassammata peqqissutsikkut 
nalunaarsorsimaffiit tamavimmik misissorneqarput.  
Ukiut tallimat ingerlaneranni ilisimatuutut ilinniarnermi (PhD) siunertarineqarpoq 
Kalaallit Nunatsinni tingukkut aseruuttoornermi nakkutilliiveqalernissaq aammalu 
tunillaassuineq annikillisinneqarnissaa. 
Kingunerisat 
Kalaallit katillugit 671-it Kalaallit Nunatsinni Danmarkimilu najugallit misissuinitsinni 
peqataapput.  
Peqataasut tuniluuttumik tingulluummik tunillatsinnikut tunillatsinneqanngittullu 
timimikkut misissortinneri aaversinnerisalu inerneri sanilliutissagaanni assigiipput. 
Kalaallit qallunaanut sanilliullugit imigassamik atuinerat annikinnerugaluartoq 
aaversinnerini tinguup kisitsisai qullasinnerupput. 
Taqarorluni ikiaroornartutalimmik kapoortarneq Danmarkimi atugaasinnaavoq. 
Kalaallit Danmarkimi najugallit taqarorlugu ikiaroornatutalimmik kapoortartut 
ikikkaluartut tuniluuttumik tingullunnermik tunillaasuusisinnaanerat 
peqqutaasinnavoq. 
Misissueqqissaarnerup takutippaa ukiut qulit ingerlaneranni tuniluuttumik 
tingulluummik type B-mik tunillatsissimasut tunillatsissimanngitsuniit sanilliullugit 
sivikinnerusumik inuuneqartut. 
Inerniliineq 
Uppernarsarparput aaversinnerni tingullunnerup suussusaanik misissuinermi (HBV, 
HDV aamma HCV) kalaallit Danmarkimi najugalinni kalaallillu Kalaallit Nunatsinni 
najugalinni assigiittut. 
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Tassunga peqqutaasorivarput inuit nutsinnginnerminni tuniluuttumik tingulluummik 
tunillatsissimanerat. Misissuinitsinni aamma uppernarsarparput 
inersimasunngornermi tingulluummik tunillatsittoqarsinnaammat. Kalaallit 
Nunaanni taqarorluni ikiaroornatutalimmik kapoorineq atugaanngilaq. Misissuinitta 
takutippaa kalaallit Kalallit Nunaata avataannut nutsernikut taqarorlutik 
ikiaroornartutalimmik kapoorinermik atuisalersinnaanerat. Taannalu pillugu 
tuniluuttumik tingulluummik tunillatsissinnaanerup ilimanassusaata 
qullasinnerulersissinnaanera. 
Ilimagaarput imigassartortanngikkaluaraanniluunniit inuiaassuseq apeqqutaalluni 
aaversinnermi tinguup kisitsisai assigiinngissinnaamata. Tuniluuttumik 
tingulluummik tunillatsinnikut timimikkut misissortikkaluarlutik aaversikkaluarlutillu 
takuneqarsinnaavoq tunillatsinnikuuneq napparsimassutiginngikkaat. 
Misissuinitsinni paasivarput tuniluuttumik tingulluummik tunillatsissimasut 
inuunerat allanut sanilliullugit sivikinnerusoq. Taanna pillugu isumaliutigaarput 
tuniluuttumik tingulluummik tunillatsissimaneq siornatigut ilimagisamiit 
aarlerinarsinnaasumik nappaataasinnaamat. 
Peqqissutsikkut sunniutit  
Timikkut misissortinnermi tuniluuttumik tingullunneq type B eqqaamaneqartarnera 
annikilliartorpoq. Nalorninarpoq tingullunnerup kingunerisinnaasai 
toqussutigineqarsinnaasut nanineqartarnerlutik. 
Tuniluuttumik tinugullunneq suli takussaavoq. Nunatsinni ineriartorneq malillugu 
periarfissaqarluarpoq tuniluuttumik tingulleq eqqumaffigineqarsinnaanera. 
Periarfissat ilagai Kalaallit Nunatsinni nalunaarsorsimaffimmik katersuiffittaarneq. 
Paasissutissat tingulluummik tunillatsinnikunut tunillatsissimasinnaasullu 
nalunaarsorneqarsinnaaniassammata. Tassunga atatillugu atorneqarsinnaasoq 
ulluinnarni timikkut misissuinermi misissueqqisaarnernilu. 
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Tingullunnermik nappaateqarneq qanorlu katsorsarneqarsinnaanera 
eqqumaffigineqarnermi paasinninneq annertunerulersissinnaavaa. Taassumap 
kingunerisinnaavaa kingunerluutaasinnaasut ikilinerat. 
Inuit siornatigut tuniluuttumik tingulluummik tunillatsissimanngitsut 
illersuutilatimmik kapitinneqartalinissaat siunissami kissaatigaarput. 
 
Qinngorput, Nuuk, Greenland
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CHAPTER 1. INTRODUCTION 
This dissertation is based on research questions originating from clinical 
observations in relation to clinical work and living in Greenland.  
Hepatitis B is a viral infection (HBV). Globally it is estimated that 257 million people 
are chronically infected with the virus (CHB) causing death to over 800,000 people in 
2015  (4,5). The risk of dying because of CHB increases over time due to cirrhosis, 
end stage liver disease and liver cancer (hepatocellular carcinoma). HBV-infections 
are endemic in Greenland and earlier studies show a high prevalence of HCC,  
although this did not match the prevalence of HBV-infections (6). There is evidence 
that the risk of acquiring HCC or liver cirrhosis is related to genotypes of the HBV (7). 
Male gender, alcohol consumption, co-infections with additional viruses are other 
risk factors of HCC and liver cirrhosis on HBV-infection (7,8). Registers have inherent 
limitations on diagnosis and on causes of death, and HBV-infections have not been 
formally monitored in Greenland. The knowledge on the cause of HBV-infections in 
the Greenlandic population is therefore limited. 
We made a cross sectional study among Greenlanders in Denmark (2) comparing the 
findings to a cross sectional study made in Greenland (1,2,9,10). Through a thorough 
review of all available electronic Medical Records (EMRs) and registries in Greenland 
we made a follow-up study on HBV-infections and on overall death on a cohort from 
Greenland (3). We did a systematic review on HBV-infections on Inuit in the 
circumpolar region (11). We helped work-up, monitoring and treating HBV-infected 
in Greenland. 
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CHAPTER 2. BACKGROUND 
EPIDEMIOLOGY GLOBALLY AND IN GREENLAND 
HBV-infection is a global health problem and may cause end-stage liver disease 
including liver cirrhosis and hepatocellular carcinoma. Due to the poor prognosis, 
HCC is the third most common cause of cancer related death. In the arctic region 
HBV-infection differs among indigenous peoples. HBV-infection is known to be 
endemic among the Arctic Inuit, but varies between Inuit populations (11). The 
burden of disease seem to vary in different regions of the world and in the 
circumpolar region (8). The concern on infection is also related to other risk factors 
such as co-infections, lifestyle factors, gender, age at infection and age,  but also in 
relation to the type of HBV (8). In Inuit in regions of Greenland prevalence of HBV 
has been found to be as high as 29% (9). A more benign course of CHB has been 
suggested among HBV subtypes in Greenland and Canada due to a low registered 
incidence of HCC (6,9,12–14). Universal vaccination of newborns reduce spread of 
HBV and hereby the HBV related risk of HCC (15,16). 
NATURAL HISTORY OF THE HBV 
The Hepatitis B virus was first discovered in the 1960s (17,18). It was referred to as 
“serum hepatitis”, and was associated to the “Australian Antigen” now known as the 
hepatitis B surface antigen (HBsAg).  The structure of the hepatitis B virus has been 
investigated since discovery of its antigenic properties and through electron 
microscopy in the 1970s. Cloning and investigation of the viral genome has identified 
the HBV as a member of the Hepadnaviridae. The DNA encode structural viral 
proteins as well as a viral DNA polymerase. In the human body the viral proteins give 
rise to antigens.  HBsAg and HBeAg (hepatitis B e antigen) can be detected I serum 
(19) as they are secreted from hepatocytes upon viral replication, while HBcAg 
(hepatitis B core antigen) can be detected in liver biopsies (20). The specific 
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immunoglobulin antibodies to the above mentioned antigens anti-HBs (antibody 
against HBsAg), anti-HBe (antibody against HBeAg), and anti-HBc (Immunoglobulin 
M antibody against HBcAg [anti-HBc-IgM], immunoglobulin G against HBcAg [anti-
HBc-IgG] or total immunoglobulins against HBcAg [anti-HBc-total]) can be detected 
in serum in relation to infection (21,22).  
The polymerase chain reaction (PCR) analysis method on amplifying small sections 
of HBV DNA has given an opportunity for further sensitive hepatitis B analysis on 
ongoing infections, genotyping and mutations.  Also, the migration (routes of 
infection) of the HBV through continents on migration of infected people over the 
history of time can now be assed (23–25).  
The overlapping reading frames in the HBV genome leads to constrains in possible 
mutations due to affection on more than one reading frame (26) yet, mutation rates 
are high compared to other DNA viruses (27).  
Genome sequencing has led to classification of HBV into 10 genetic subtypes or 
genotypes (A-J) (21) based on more than 8% diversity on full genome sequencing or 
less than 4% diversity on S-gene sequencing and even further into sub-genotypes 
with a number attached to every genotype letter (example A1 or B5). Specific HBV 
sub-genotypes predominate in different parts of the world (8,21,25,26). The 
different genotypes and sub-genotypes are argued to have different potentials on 
degrees of inflammation and carcinogenic properties on the liver (8,21,28). In 
Greenland the sub-genotype B5 (formerly B6) predominates although more 
subtypes and genotypes (A,D) reside (9,29). B5 is argued to be a more benign 
genotype/ sub-genotype of HBV on both inflammation and carcinogenesis, although 
many aspects are not fully answered (8,9,25,28,30). The risk of a CHB carrier state is 
partly due to the age at infection. Vertical transmission of HBV from an infected 
mother to the child in the perinatal period is possible and the risk of chronicity on 
infection is reported to be as high as 90% (31). Risk of CHB due to horizontal 
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transmission of HBV during childhood has been stated to be 25% (32) while around 
10% during adulthood (33).  
 HBV-infection does not cause liver injury by itself. Hepatic injury is related to the 
immune response. Different scoring systems of hepatic injury exist  based on the 
degree of inflammation and scaring (fibrosis or cirrhosis) by visualization on liver 
histology (34). Histopathology is one way of evaluating degree of disease burden. 
The risk of HCC have been associated to different factors such as especially the viral 
genotype C, mutation in the Pre-Core or Core promotor regions and interpolation of 
HBV cccDNA into the host DNA. Also, host factors such as male gender with age 
above 40, family history of HCC, co-infection with hepatitis D or C virus, alcohol abuse 
and aflatoxin exposure are recognized risk factors. HCC usually develops in patients 
with liver cirrhosis (35). Factors of known importance on chronic inflammation and 
cirrhosis are HBV DNA load, high levels of HBsAg, HBeAg positivity and age at 
infection. It is still uncertain which risk factors play the major role in carcinogenesis 
(7,8). Liver cancer was predicted to be the sixth most commonly diagnosed cancer 
and the fourth leading cause of cancer death worldwide in 2018 (36). 
Counting all available  death certificates in a time period from 1995 through 2013 
only seven have been registered to have died with or of a viral hepatitis according to 
the data bank from the National Board of Health in Greenland (37). 
DIAGNOSTICS AND PHASES OF HBV DISEASE 
Most HBV-infections progress without any clinical manifestation although infection 
can sometimes be diagnosed as an unspecified acute hepatitis with symptoms in 
forms of loss of appetite, dark urine, fever, joint pain, nausea and vomiting, fatigue 
and jaundice (38). 
As no symptom is pathognomonic to only HBV-infection further diagnostics is 
needed to interpret the hepatitis disease. By time, serology, virology and by liver 
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biopsy hepatitis B can be divided into acute or chronic hepatitis B infection and can 
be further specified into theoretical infectious phases (22).  
Based on serological findings and a time period of infection lasting less than six 
months an acute hepatitis can be defined (39). CHB is divided into different phases 
based on serology, aspartate transaminase (ALT) levels in serum and liver biopsy 
findings (21,40). These phases are further contemplated on in relation to treatment. 
The formal goal of treatment on CHB-infection is to reduce the risk of liver disease, 
liver failure and HCC. Anti-viral therapy is used to reduce burden of disease in case 
of an immune reactive phase or upon reactivation to prevent aggravation in 
inflammation and fibrosis of the liver (21,41).  
Earlier studies have suggested  immune tolerant or inactive phases among Inuit in 
Greenland (42–44) although very few studies have interpolated liver function tests 
in their HBV-studies  (9,45) and till this date none on liver biopsies. 
Patients with immune-tolerant CHB-infection and without treatment are suggested 
to be monitored at least every six months with serum ALT (30). Anti-viral treatment 
should be considered on behalf of ALT, viral load and on liver biopsy evaluation if 
attainable (21,30). 
THE SETTING 
Eighty-one percent of Greenland is covered by ice (the Greenland ice sheet). All 
towns and settlements are located along the coastal line. No roads exist between 
towns or settlements. Travel is only possible by water or air and with seasonal 
differences. Domestic transportation types include plane, helicopter, snowmobile, 
dogsleds and boats (46). Greenland is a self-governing region within the Kingdom of 
Denmark.  Greenland became a Danish colony in 1721 and a Danish County in 1953. 
A Greenland Home Rule Government was established in 1979. Self-rule was 
established on June 21th 2009 (47). Citizens of Greenland still have Danish 
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citizenship. The population density is the lowest in the world. The population in 
Greenland is around 56-57000.  Most are of Inuit descent (Thule culture/Neo-
Eskimo) while a minority are migrants from Denmark (mostly Caucasian) (48). 
Approximately 6-7000 people in Greenland were born outside Greenland (most of 
these born in Denmark). Around 13-18,000 persons in Denmark have been defined 
as being of Greenlandic descent (2,47). 
On aspects of blood borne diseases Intravenous drug use has been considered 
nonexistent in Greenland before (49,50) and current injecting drug users (IDU) are 
still not part of present clinical practice (personal report from Karsten Rex [KR]). On 
venereal diseases gonorrhea and chlamydia infections are still a major problem in 
Greenland (51). Hepatitis B is one of many known infectious hepatotropic viruses of 
which some reside in Greenland. Other hepatotropic viruses have been recorded in 
Greenland including the hepatitis A (HAV), D (HDV), E (HEV) and C virus (HCV) 
(29,45,49). Alcohol use has been associated to health problems and deaths, although 
very little research exist on liver disease on the basis of alcohol consumption among 
Inuit (52–55). Risk of liver disease on alcohol consumption may rise with viral 
hepatitis (56,57). 
All health care services are publicly funded in Greenland. These include free 
vaccinations, treatments and all visits to the health care providers.  
HBV-VIRUS INFECTIONS IN GREENLAND 
The first introduction of HBV (Genotype B5) into the population of Greenland dates 
back to the very first Thule-peoples migration to Greenland from the Bering Strait 
region approximately 900 to 700 years before present (25). Earlier studies dating 
back to the 1970s have shown endemicity in different parts of Greenland (11,42–
44,49). Studies have hinted a benign course of disease (9,12,58). Infections with 
hepatitis D virus (HDV) has been studied to some degree earlier (29,42) and caused 
concern (45). HBV- and HDV-infections among Greenland migrants have not been 
HEPATITIS AMONG GREENLANDERS IN DENMARK AND IN GREENLAND, AND THE OUTCOME OF CHRONIC HBV-
INFECTION IN GREENLAND 
34 
studied (1,59). It is debated how HBV-infections are transmitted in general in the 
Greenland population. HBV transmission during pregnancy, childbirth and 
horizontally due to housing conditions or sexually is plausible and might differ 
according to place and regions (9,42,43,45,49,51). As mentioned intravenous drug 
use is nonexistent in Greenland and disease transmission today due to contaminated 
blood products and needle sharing among Greenlanders in Greenland is not likely 
(1,42). Blood borne diseases can be introduced to Greenland on migration (1,50,60). 
Through decades guides on blood transfusions in Greenland have been updated now 
containing screening for HBV, although transmissions by way of this route has been 
possible (61). 
New-born and childhood vaccination programs in Greenland have differed over the 
last decades with the introduction of the HBV vaccine in 2010 (12,61–63).  
Vaccination coverage is largely unknown (62). Screening of HBV on pregnant women 
has been ongoing since the 1990s (12) with the availability of vaccination and HBIG 
administration to the newborn.  
Until this day there is no nation-wide monitoring-program on HBV in Greenland. 
Although there has been intentions to initiate such a program, this has not been set 
up. Despite recommendation, there has been no official guideline internally in 
Greenland for screening, diagnostic work-up and follow-up, although treatment 
today follows international guidelines. There has been limitations in the paraclinical 
assessment of HBV in Greenland.  
Reporting of acute and CHB is mandatory in Greenland. Pregnant women, blood 
donors and patient who are to undergo chemotherapy or immunosuppressive 
treatment are to be tested for HBV infection status (11). Antiviral treatment is usually 
not limited to the accessibility of medicine (60) which is as mentioned earlier cost 
free for the individual and also comparable to international guidelines (21,30).  
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CHAPTER 3. HYPOTHESIS AND AIMS 
A unique benign long-term outcome of HBV-infection has been suggested in Greenland, as 
described in detail earlier. A systematic follow-up on the HBV-infected in general or in 
studies, the influence of migration on HBV prevalence, and hereby the selection of survivors 
on HBV-infection has not been thoroughly explored. The overall aim of this PhD study was 
to elucidate disease burden of HBV-infection in a Greenlandic population in Greenland and 
in Denmark. This assessed by comparing Greenlanders with frequent HBV-infections from a 
cross sectional study in 1998 in Greenland to migrated Inuit Greenlanders from a 
subsequent cross-sectional study in Denmark in 2006. In addition, assessing overall survival 
and disease burden over a course of ten years. This through a thorough systematic review 
of all EMRs and registers on attenders from the 1998 cross-sectional study in Greenland also 
taking into account health factors such as diet, smoking, alcohol intake, body mass index 
and liver function tests from the clinical study.  A secondarily aim was to cultivate an idea 
for a future monitoring program and containment of HBV-infections in Greenland while 
working in a Greenlandic environment. The PhD dissertation comprise primarily of three 
individual studies, addressing specific aspects of the above. 
1. The aim was to report prevalences of serological markers on hepatitis B, D, and C virus 
infections among Greenlanders living in Greenland and who had migrated to Denmark, also 
taking into account objective measures of hepatic disease (study 1 (1)). 
2. The aim was to describe associations between liver biochemistry, reported alcohol intake 
and HBV-infection, also taking into account ethnicity, BMI, gender, age and diet in an Arctic 
population (study 2 (2)). 
3. The aim was to do a 10-year follow-up study on a population of Greenlanders with 
frequent HBV-infections concerning hepatitis B diagnostics, cirrhosis, end stage liver 
disease, HCC, vaccinations, other liver diseases and all-cause death using all available EMRs 
and registries from Greenland. Also, linking clinical study results on HBV-status, liver 
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function tests, smoking habits, drinking habits, diet and body build measures to all-cause 
mortality analyses (study 3 (3)). 
In addition, monitoring aspects and containment of HBV-infections were met talking to 
medical personnel that had been working on Hepatitis B in Greenland and in the Arctic 
during the latest decades trying to enhance diagnostics and work-up possibilities. 
Moreover, by working in different parts of Greenland and with hepatitis patients from all 
over Greenland during the course of the 5-year part time PhD and beyond. 
 
Aalborg, Denmark and Nuuk, Greenland 
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CHAPTER 4. METHODS 
STUDY AREA AND POPULATIONS 
EAST AND WEST GREENLAND 
Participants in Greenland were men and women aged 50 through 69 years in 1998. 
Eligible persons were identified through the National Civil Registration System 
(NCRS) where all persons born in “The kingdom of Denmark”: Denmark, the Faeroe 
Islands and Greenland are recorded. A random sample of 25% of men and women 
living in Nuuk in West Greenland were identified and invited to be part of the 
investigation (total population 12,909; in the age group 1,920; year 1998) (10). All 
inhabitants in this age group living in the town of Tasiilaq (total population 1,724; in 
the selected age group 184; year 1998) or in the surrounding settlements (n=152) 
(Tiniteqilaaq, Sermiligaaq, Kulusuk and Kuummiut) in East Greenland were invited 
(total population 1,093; in this age group 152; year 1998). The potential participants 
in Nuuk had initially been selected using the hospital registration system in Nuuk in 
1998 on which 1920 persons were recorded. This had not been updated and the 
selection was validated by comparing it to the National Civil Registration System 
(NCRS).  Of the 480 persons initially selected in Nuuk 255 persons had moved or died 
and therefore could not be contacted on the registered addresses and therefore not 
found eligible for the study. Of the remaining 225 persons, only 14 refrained from 
attending (6%).  In East Greenland, the NCRS was used in both the settlements and 
in the town and only nine persons out of 161 potential participants from the 
settlements and 13 out of 197 potential participants from the town were not eligible 
due to latency in reporting of death or changing of addresses. This was validated by 
the local porter or the village health care provider. Only one refrained from attending 
in the settlements (0.7%) and 11 (6%) from the East Greenlandic town Tasiilaq. In 
total 535 persons participated out of 561 invited in Greenland. 
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SAs ticket receipt to Greenland anno 1998 
DENMARK 
For the cross-sectional survey in Denmark in 2006 (from two major counties Aarhus 
and Aalborg in Jutland) individuals born in Greenland with at least one parent born 
in Greenland were included. Moreover, Greenlanders aged 40 through 49 years were 
included on basis of the Greenlandic population size in the regions investigated. In 
total 312 subjects born in Greenland were identified through the NCRS. We were able 
to establish contact to 220 subjects. Here, 54 persons were excluded on basis of the 
inclusion criteria and 30 eligible participants refrained. We could not establish contact 
to 92 subjects. Of the 136 Inuit investigated in Denmark 37 were aged 40 through 49 
years. 
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Figure 1. Flow-charts of inclusion of participants in Greenland in 1998 and in Denmark in 2006  
Eligibility for the 10-year (registry) follow-up study relied on informed consent from 
the 1998 clinical study in Greenland.  
 
  
INVESTIGATIONAL PROCEDURES 
A letter of invitation was delivered to each subject by the local hospital porter or the 
nursing station attendant in Greenland while using the Danish postal service in 
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Denmark. Non-responders were invited three times. The investigation took place at 
the local hospital or nursing station or, by request, at home visits. A physical 
examination and venous blood sampling was performed by one of the investigating 
doctors Stig Andersen (SA) or Peter Laurberg (PL), by Bodil Hvingel (BH) in Greenland 
and by KR and SA in Denmark. Examination included height without shoes, weight in 
indoor clothing, any major disabilities, scleral jaundice, spider naevi and signs of 
hepatic decompensation such as confusion, jaundice, fluid retention and cachexia. 
Body mass index (BMI) was calculated as weight in kilograms divided by height in 
meters squared. Participants were interviewed by an interpreter or by one of the 
investigational physicians, who completed the questionnaire in either Danish or 
Greenlandic, as appropriate for the subject. The same interpreter Karoline Berglund 
was used in Nuuk, Tasiilaq, and all settlements.  Information on lifestyle patterns and 
dietary habits was obtained by using questionnaires. Questions were asked as 
written in the questionnaires.  
ALCOHOL 
Twelve grams of alcohol was the equivalent of one unit. Average alcohol intake 
above two units per day for women and three for men defined an intake above the 
recommended levels. Alcohol intake was also categorized into two groups 
(never/ever) and five groups (never, drinks 0-7 units weekly, drinks 8-14 units 
weekly, drinks 15-21 units weekly and drinks >21 units weekly). 
DIETARY HABITS 
Participants were classified based on the number of days per week that the main 
meal consisted of Greenlandic food items (that is, Greenlandic seal, whale, wild fowl, 
fish, reindeer, musk ox and hare) (10). 
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SMOKING 
Smoking was categorized into either two groups (never smoked/have smoked) or 
five groups (never smoked, ex-smoker, has <10 cigarettes daily, has 10-20 cigarettes 
daily and has >20 cigarettes daily). 
INUIT ANCESTRY 
Inuit ancestry was defined as being born in Greenland and having had at least one 
parent born in Greenland.  
 
BODY MASS INDEX 
Body mass index (BMI) was calculated as the weight (in kilograms) divided by the 
height (in squared meters). A BMI below 18.5 kg/m2 was defined as low, and a BMI 
above 25 kg/m2 was defined as high. A BMI between 18.5-25 kg/m2 was categorized 
as normal (64). 
 
VENIPUNCTURE 
A venous blood sample was drawn using minimal tourniquet, separated and stored 
at -20 C. Blood samples were blinded using an 8-digit code, and analyzed in random 
order. Blood sampling was omitted with four participants in Denmark and with one 
in Greenland, in compliance with the participants’ choice. 
CLASSIFICATION OF HEPATITIS EXPOSITION 
The participants were classified, based on HBV serology analyses, as being currently 
infected (if HBsAg was positive), as having been previously exposed (if HBsAg was 
negative and anti-HBs and/or anti-HBc-total were positive [due to a lack of HBV-
vaccination in this population in this time-period]) and as being never exposed (if all 
of the markers were negative) (1,9). 
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DATA SOURCES AND REGISTRIES 
Due to the blinding of individual identification after the first cross-sectional study, 
the Population Registry of Greenland (‘Sundhedsbasen’) was used to find every 
participant’s ten digit Danish Social Security Number for subsequent register 
analysis. This done through the linking of names, age and address at time of 
investigation of every participant to a specific social security number. A social 
security number could be addressed strictly to all but two participants from the 
cohort, for whom register data hereby could not be achieved. EMRs and registries 
were accessible and manageable. The earliest documentation in the EMRs in 
Greenland were from the late 1990s. These included radiological scans (‘Infinnitt 
system’) and descriptions (‘Infinnitt’, ‘Æskulap lægeklinikken’), old (‘Æskulap 
Lægeklinikken’, ‘Æskulap Tasiilaq’, ‘Journaler i word’) and the new joined EMRs 
(‘Cosmic’) in Greenland as well as the nation-wide electronic available blood sample 
analysis platform (‘BCC-lab’). Register data from the Danish Biopsy Registry (‘Pato 
Bank’) was accessible and also from the Danish Death Registry 
(‘dødsårsagsregisteret’) through the Chief Medical Officer of Greenland. The 
documentation of death causes from Greenland into the Danish Death Registry has 
been ongoing since 1973 in Denmark with addition of death causes from Greenland 
in 1983 (65). The Danish Biopsy Registry was established in the 1970s, although 
nation-wide registry was not implemented until 1997 (66).  
LABORATORY ANALYSIS 
SEROLOGY, VIROLOGY, HBV GENOTYPING, QUANTIFICATION OF HDV 
AND HCV, AND BIOCHEMISTRY 
Serology, virology, HBV genotyping, quantification of HDV and HCV, and 
biochemistry has been described in detail in earlier reports (1,9,67–69). 
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STATISTICAL ANALYSES 
Random selection of participants in Nuuk was done using MedStat (Astra, 
Albertslund, Denmark). Data were processed and analyzed using Corel Quattro Pro 
X3 (Corel Corporation, Ottawa, Ontario, Canada), the Statistical Package for the 
Social Sciences version 13.0 (SPSS Inc., Chicago, Ill., USA), using Stata version 15.0 
Statistics/Data Analysis (Texas StataCorp, USA) and Microsoft Excel 2016. Statistical 
significance was considered on the basis of a 2-sided p-value of 0.05 and 95% 
confidence intervals (70,71). Data were provided as medians with 25th and 75th 
percentiles when they did not follow the normal distribution. Chi-squared test was 
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used for comparison of proportions and Mann–Whitney U-test (Wilcoxon rank-sum 
test) for comparison of median values.  
Statistics for the individual studies has been described in detail in our earlier reports 
(1,2). In short, multivariate logistic regression models were used in elucidating 
factors of importance concerning HBV exposure and multivariate linear regression 
models on factors on LFT levels. 
Moreover, entry and exit time (time of censoring or death) for survival in study 3 
were established according to the clinical study in Greenland. Entry time for 
participants from Nuuk was on June 20th 1998 and for participants from East 
Greenland on November 16th 1998. Censoring time being a ten-year follow up. Date 
of death was manually extracted from the Greenland Population Registry, the EMRs 
and these data were cross-validated with the Danish Cancer and Death Registry 
(DCDR). The specific registered causes of death were obtained from the DCDR (3). 
Logical, potential accessible predictors (covariates in multivariate survival analyses) 
of time until death were obtained from the clinical cross-sectional study. The 
stepwise function was computed in Stata (significance level 0.2) for calculation of 
covariates of significance, but ultimately not used in model fitting due to the risk of 
overfitting. The covariates that were used in analyses of survival included age in 
years (a continuous variable), Inuit origin (yes/no), place of living (West or East 
Greenland), gender (male/female), diet categorized into two groups (main meals 
dominated by Greenlandic food items: yes/no), liver function tests (continuous 
variables), BMI (a continuous variable or in the categories mentioned above), alcohol 
intake (in the categories mentioned above), smoking status (in the categories 
mentioned above) and HBsAg (yes/no) or HBV-infection status in three categories 
(present, past or never) (3).  
The data distribution that assessed outliers, normality, collinearity and 
multicollinearity was evaluated by using Q-Q plots, the Shapiro-Wilk W test, 
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correlation tests and visual plots (multicollinearity automatically, collinearity by the 
pwcorr command and visually by the graph matrix command in Stata). The possible 
transformation to normality or categorization was also evaluated. Incidence rates, 
incidence rate ratios and hazard ratios were estimated based on infection status. 
Dates of birth were used as a left truncation point (using age as an underlying time 
scale) in the adjusted survival analyses also to control for confounding by age. Before 
Cox-regression assumptions on non-informative censoring was tested and met. The 
proportional hazard assumption on infection status was assessed and met using 
plotted cumulative hazard estimates (Nelson-Aalen Cumulative hazard estimates) on 
a log scale (log-log plot of survival, stphplot in Stata), and formally tested  using 
Schoenfeld residuals testing (estat phtest in Stata) (3).  
Confounding effects and interactions of possible predictors (gender, alcohol, BMI, 
Inuit ancestry, place of living, smoking, diet and high age) on infection status and 
death were tested using the Mantel-Haenszel and Mantel–Cox methods. Effect 
modification on infection and death was tested using predictor as an interaction 
term in Cox analysis. Adjusted cox-models with confounding variables and 
interactions were compared for enhanced statistical explanation using Likelihood-
ratio tests for nested models (3). 
Parametric model fit and PH assumption was evaluated visually through a ‘log (-
log(predicted survival)) plot’ on infection status. Available parametric functions were 
compared with the Akaike information criterion (AIC) for relative model quality. 
Martingale residuals were estimated and plotted against the linear 
predictor/covariate for detection of outliers. Cox-Snell residuals were visualized in 
histograms for normality and plotted against cumulative hazard function for 
visualizing model fit. Deviance residuals for uncensored data were plotted against 
the linear prediction to visualize homoscedasticity, outliers and model fit for 
parametric models. Fitting of parametric models were primarily done for an 
explanatory model and used (with precaution) on a prediction model for computing 
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predicted median lifetime differences on infection status. The Weibull function for 
the adjusted parametric regression survival analysis had the best fit judging on AIC 
and residuals when compared to other possibilities using Stata, and was used in 
estimating predicted median survival times. Participants were divided into 
subgroups based on place of living and ethnic origin in attempt to further examine 
potential regional differences (confounding) on survival. Missing data was looked at 
on every step of statistical analyses (3). 
ETHICS 
The studies were conducted according to the guidelines laid down by the Declaration 
of Helsinki. The regional ethics committee for Viborg and Nordjylland County 
approved the study in Denmark (VN-20060038). Ethical approval was obtained for 
the initial study from the Commission for Scientific Research in Greenland in 1998 
(j.no. 505-31), with supplementary approval for hepatitis diagnostics in 2004 
(J.no.505-99). The Committee of Research Ethics in Greenland granted acceptance 
of the register study for follow-up on the cohort population as did the Chief Medical 
Officer of Greenland (KVUG ref.no. 2016-20). The Board of Prevention and Health in 
Greenland approved and supported access to health data from the EMRs (November 
3rd 2016). All subjects gave informed written consent in the clinical studies in Danish 
or Greenlandic by participant choice.  
MONITORING HEPATITIS IN GREENLAND 
Aspects on monitoring HBV-infected in Greenland relied on clinical work in 
Greenland from 2010 and onward. HBV and HDV problematics from all over 
Greenland were handled with correspondence with hepatitis experts from Denmark 
and from the circumpolar region.  A systematic review on HBV diagnostics, 
vaccination, treatment options and future assessment on HBV in Greenland and 
status in the circumpolar region was assessed (11). Research aspects on monitoring 
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capabilities on indicators for other diseases using the different EMRs in Greenland 
was assessed (72). 
 
Nuuk, Greenland 
 
Itilleq, Greenland 
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CHAPTER 5. RESULTS 
STUDY 1: SEROLOGICAL MARKERS OF HEPATITIS B, D AND C VIRUS 
INFECTION AMONG GREENLANDERS IN GREENLAND AND DENMARK 
In study 1 prevalences of serological markers of hepatitis B, D, and C virus infection 
among Greenlanders living in Greenland and who had migrated to Denmark was 
surveyed also taking into account objective measures of hepatic disease, lifestyle 
factors and comparing weight, height and liver function tests on infection status (1). 
INVESTIGATION IN GREENLAND 
Participation rate in the population-based survey in 1998 in Greenland was 95%.  
Table 1 includes the descriptive data of participants from Greenland (3).  
More non-Inuit were men (p<0.001) living in one of the investigated towns (p<0.001) 
in concordance with the demography in Greenland (migrant work force with male 
non-Inuit predominance).  All but seven Inuit had both parents born in Greenland 
and one female in this group had an ongoing HBV-infection. 
Serological signs of hepatitis B exposure are shown in Table 1 (1,3). None had signs 
of liver disease on the physical examination.  
The absolute and relative number of hepatitis B infected differed among genders 
with the highest number of infected among male Inuit in settlements on the east 
coast (29 infected, 34.5% of Inuit in settlements in the age group). Inuit males or 
females from villages comprised approximately the same proportion on overall 
percentages on gender (Inuit males from villages represent 27.2% of all males while 
Inuit women from settlements represent 27.9%). Although, there was no significant 
difference on distribution of ongoing HBV-infection between genders (Inuit) in the 
settlements (p-value 0.105) on chi-squared testing. Distribution on markers of HBV-
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infection did differ on gender in both towns (Nuuk, p=0.027 and Tasiilaq, p=0.046) 
while not in the villages (p=0.81).  
Table 1. Characteristics of participants from West and East Greenland (3). 
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Moreover, there was no gender difference among Non-Inuit on markers of HBV-
infection (p=0.930). One fourth of both genders had markers of HBV (all born in 
Denmark). Only one (man) had a history of HBV-vaccination going through the 
Greenlandic EMRs. On Anti-HBc-total serology 11% of non-Inuit women (n=2 out of 
18) while 21% (n=16 out 75) of Non-Inuit males were positive.  Sixty-one participants 
were HBV-DNA positive, 38 million copies/mL was the highest viral count and 
genotype B predominated (9). Five had a positive anti-HDV and none with 
measurable HDV-RNA (1).  
INVESTIGATION IN DENMARK 
The participation rate in Denmark was 52.2%. Of the 136 participants, 33 were men 
and 110 had both parents born in Greenland. Three had a history of earlier intravenous 
drug use (1). 
Overall median (25th; 75th percentiles) age at sexual debut among Greenlanders in 
Denmark was reported to be 16 (15; 17) with missing data on 13, while debut was 
14 years to 18 years among the 5 infected with missing data on one participant and 
15 (15; 17) among never exposed. Between genders median age for reported sexual 
debut was 15 (15; 17) for men and 16 (15; 17) for women. Number of sexual contacts 
did not differ between genders overall on a 12 month period (p=0.61), with only 6 
persons having more than one sexual partner, although ranges for men were null 
through 30 and null through 6 for women. 
Few had yellowing of the sclera (eight participants) or spider neavi (one participant), 
and these signs did not associate to HBV-infection. No participant had signs of 
decompensation. There was no statistical association between reported hepatitis or 
vaccination and serological markers on HBV “(p=0.69 and p=0.86)” (Rex et al. 2012, 
695) (1). 
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Anti-HDV was found in only one participant. Exposure to both HBV and HCV was 
found in one participant. 
HBsAg was found positive in five women and one man and none were exposed to 
HDV or HCV (1). Range of HBV-DNA was null to 200 copies/mL. We found no clinical 
signs of disease on these and no difference on LFTs or body build when comparing 
participants on HBV infection status (never, past, present) (1). 
OVERALL ON HBV 
No associations were found between measurable parameters used in the clinical 
studies and current HBV infection in the crude comparisons or in the multivariate 
linear regression models (1). Markers on HBV in the studied migrated Greenlandic 
population in Denmark resembled the population studied in Greenland with no 
statistical difference on prevalences (1). 
STUDY 2: ASSOCIATIONS TO LIVER BIOCHEMISTRY 
Study 2 aimed to describe associations between liver biochemistry, reported alcohol 
intake and HBV-infection, also taking into account ethnicity, BMI, gender, age and diet 
among participants from study 1 (2). 
Overall, data on 671 participants were investigated. Alcohol consumption was more 
prone among non-Inuit (90%) than Inuit (70%). Among Inuit participants East 
Greenlanders had the highest alcohol intake while the lowest consumption was in 
Nuuk (the capital) (2). 
HBV, BMI and alcohol (also on behalf of below/above recommended consumption) 
distributions did not differ on participants from Denmark when grouping them into 
two age groups (below or above age 50 years), although distribution on gender was 
different (p=0.007). 
HEPATITIS AMONG GREENLANDERS IN DENMARK AND IN GREENLAND, AND THE OUTCOME OF CHRONIC HBV-
INFECTION IN GREENLAND 
54 
Multivariate linear regression models on the 441 Inuit and 94 non-Inuit participants 
from Greenland (not on participants from Denmark as biochemical analyses were 
done separately) showed evidence of increasing AST and GGT, and decreasing ALK 
on alcohol consumption (2). Non-Inuit origin showed evidence of lower AST 
(p<0.001), GGT (p<0.001) and ALK (p<0.001) compared to Inuit (2). Advancing age 
increased bilirubin (p<0.007). Female gender was associated to lower AST (p<0.04) 
and GGT (p<0.052). Consumption of traditional Greenlandic diet showed evidence of 
higher ALK (p<0.001) and lower albumin (p<0.001) (2). 
Increasing BMI associated with higher AST (p<0.013), GGT (p<0.001) and albumin 
(0.007). None of the above mentioned factors associated with LFTs on other analyses 
and importantly neither did infection with HBV (2). 
Multivariate logistic regression analyses showed Inuit origin to be associated with 
GGT above normal “(p<0.001; odds ratio (OR), 95% CI:8.8, 3.8-21)” (Rex et al. 2016, 
6) (2). Also, increasing BMI and alcohol consumption was correlated to high GGT (2). 
AST above normal for each gender correlated to alcohol consumption and Inuit 
ethnicity. Current infection with HBV did not correlate to abnormal AST (or any LFT) 
or modified the association between AST and alcohol consumption (2). Only Inuit 
origin seemed to be an effect modifier on AST alone, while not on any other LFT (2). 
STUDY 3: A 10-YEAR FOLLOW-UP ON GREENLANDERS WITH 
FREQUENT HBV-INFECTIONS 
In study 3 the aim was to do a 10-year follow-up study on the population of 
Greenlanders from Greenland investigated in Study 1 concerning hepatitis B diagnostics, 
cirrhosis, end stage liver disease, HCC, vaccinations, other liver diseases and all-cause 
death using all available EMRs and registries from Greenland. Also, linking clinical study 
results on HBV-status, LFTs, smoking habits and drinking habits, diet and body measures 
to all-cause mortality  analyses (3). 
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The characteristics of participants is presented in Table 1 (3). A flowchart of the 
participants is shown in figure 2. One third of the total cohort had died during the 10-
year follow-up period. Thus, there were 181 events (deaths) (34%) and 352 censored 
(66%) as 352 were known to be alive at follow-up. 
 
Figure 2. Flowchart on a 10-year (Register and EMR) follow-up. 
As previously described, the 1998 cross-sectional study had a participation rate of 
95%. Blood samples were obtained from 531 of the 535 individuals, and 87 
individuals were HBsAg positive. All but one of the individuals were also anti-HBe 
positive. 
 
REGISTERED CAUSES OF DEATH 
The causes of death did not differ according to HBV infection status, as is presented 
in Table 2 (3). Forty-five out of the 87 individuals who were diagnosed with HBV-
infections had died at the time of the 10-year follow-up, compared to 136 of the 442 
noninfected individuals (52% vs 31%, p<0.001). Causes of death could not be 
determined from the death registry in nine patients. There were no recordings of 
HCC in the registries, but one patient without HBV-infection had HCC with metastasis 
to the lung, according to the pathology report (3).  
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Table 2. Causes of death in subjects with and without HBV-infection as reported in registries  
(3) 
 
REGISTER-BASED HBV DIAGNOSIS, KNOWN LIVER DISEASES AND 
VACCINATION 
None of the 533 participants had a registered HBV vaccination, and none had liver 
disease by 1998, according to the EMR and in compliance with the cross-sectional 
study. One participant had been screened for hepatitis and was documented to be 
HBsAg negative in 1998 according to the EMRs. Eight EMRs mentioned an HBV 
screening. One case was HBV positive in 2005 and one case was HBV positive in 2008. 
One participant (who was HBV negative in 1998) was stated to have alcoholic liver 
cirrhosis, based on a history of alcohol use, and an ultrasonography of the liver that 
showed dilated bile ducts. However, a computer tomography scan (CT scan) report 
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demonstrated no signs of liver disease. An HBV diagnostic work-up was stated, but 
results were not reported in the EMR. One participant (HBV negative in both 1998 
and 2008, according to the EMR) had cholestatic hepatitis, according to a liver 
biopsy. One participant was recorded as being HBV vaccinated by 2008 (3). 
 
HBV AND PREDICTORS 
HBV-infection status proportions did not differ with gender, BMI group or smoking 
habits, whereas it differed with alcohol consumption (p=0.025), ethnic origin 
(p<0.001; no non-Inuit participants were infected), diet (p=0.002), age (p=0.009), 
being a smoker (p=0.016) and place of living (east/west; p<0.001) (3).  
 
ASSOCIATIONS TO DEATH 
Death was associated with HBV-infection (p<0.001), smoking status (p=0.004), origin 
(p<0.001), age (above a median of 57 years, p=0.009), diet (p=0.018) and alcohol 
status (do drink vs never drink, p=0.004) but was not associated with place of living 
(p=0.08) or gender (p=0.96) (3).  
SURVIVAL ANALYSIS 
Table 3 presents the difference in survival among participants with and without HBV-
infections.  
Table 3. Survival data on Greenlanders in Greenland followed up for 10 years.  
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Survival differed markedly with HBV-infection (log-rank test for equality; p<0.001). 
The unadjusted overall median (25th; 75th percentiles) survival time was 70.7 years 
(63.4; 77.1). The median survival time was 67.8 years (61.8; 72.1) for the infected 
patients and 71.7 years (64.0; 79.3) for the noninfected patients. The risk ratio was 
1.70 (95% CI: 1.33-2.17) for the infection status. The hazard ratio was 2.03 (95% CI: 
1.44 -2.85) among the infected patients (p<0.001) when using only HBV-infection 
status in the Cox model (3). 
The hazard ratios (HR) for the adjusted cox regression analyses were higher with 
infection status (HR: 1.57; 95% CI: 1.07-2.30) and with smoking status (HR: 1.92; 95% 
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CI: 1.07-3.42). The HR for the adjusted Weibull regression model on infection status 
was 1.72 (95% CI: 1.20-2.46) (3). 
The overall adjusted predicted median survival time (predicted life span) was 70.6 
years (67.3; 74.6). The predicted life span was 64.8 years (63.3; 66.9) among the 
infected patients and 71.8 years (68.8; 75.3) among the noninfected patients. The 
median predicted lifetime difference was 6.9 years (3.2; 10.9). When using only HBV-
infection status in the parametric model and when not taking smoking, diet, alcohol, 
albumin or origin status into account, there was a predicted median survival time 
difference of 6.6 years (3). 
A sub analysis excluding violent deaths (suicides, alcohol intoxication, trauma or 
accidental hypothermia) did not markedly alter the HR of death with HBV-infection 
(HR: 1.66; 95% CI: 1.10-2.51; p=0.016) (3). 
As presented in table 3, we also made sub analyses on the East Greenland Inuit 
participants concerning survival, as HBV-infection was more prone in this group, as 
living conditions could differ between rural East and modern West Greenland and 
the probability of the same HBV genotype was higher. The crude non-parametric 
analysis on the East Greenlanders showed a risk ratio of 1.43 (95% CI: 1.08-1.90) for 
death on HBV infection status. The predicted median lifetime difference between 
the infected and noninfected patients was 4.5 years (0.8; 8.5), and the difference 
was 4.1 years when only using the HBV status in the parametric model. Finally, the 
adjusted Weibull-analysis showed an increased hazard ratio for infection of 1.59 
(95% CI: 1.07-2.36; p=0.020) (3). 
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Figure 3. Kaplan-Meier plot on HBV-infection 
status with 95% confidence intervals and 
number of participants at risk during a 10-
year follow-up using survival years from 
clinical study as analysis time. 
 
Figure 4. Cox-snell residuals against the Nelson-Aalen 
hazard function on model fit for the cox-model using 
survival years from clinical study as analysis time. 
 
Figure 5. Kaplan-Meier observed survival 
curves are compared with the Cox predicted 
curves for Hepatitis B virus infection status. 
Proportional hazards assumption on infection 
status (infected and noninfected) depicted 
using survival years from clinical study as 
analysis time  (3).  
 
Figure 6. Visual interpretation of parametric Weibull 
model on proportional hazards assumption based on 
parallelism of lines and model fit based on linearity 
using age as an underlying time scale. 
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Elements of Denmark and Greenland 
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STRATEGIES USED IN GREENLAND FOR MONITORING AND 
CONTAINING HBV-INFECTIONS.  
Unlike Alaska or Denmark, Greenland has no centralized systematic follow-up on 
patients with chronic HBV-infection (73,74). There is no clinical database in 
Greenland similar to that in Denmark, where DANHEP is a Danish Database for 
recording of cases of hepatitis B and C. It holds records of patients with chronic 
viral hepatitis admitted to hospitals in Denmark.  
Notification of CHB infection to the national register of notifiable diseases is 
mandatory in Denmark, but reporting rates are low  (74). HBV notification to the 
National Board of health in Greenland is also mandatory. Registration on infectious 
diseases show very specific numbers of Gonorrhea, Syphilis, HIV, tuberculosis and 
syphilis incidences from 2008 and forward. Registered HBV incidences are only 
shown from 2014 and forward. In total there were eight registered HBV-infections 
(seven in 2014 and one in 2016) (61). The mandatory notifications to the national 
Board of Health on HBV-infections has not been clear as there have been questions 
on whether both acute and chronic infections were to be notified and as a result, 
CHB-carriers have not been notified rigorously (correspondence with the Chief 
Medical Officer in Greenland). Only five cases of HBV-infections have been notified 
in 2017.  
Hepatitis D virus (HDV) infection is not a notifiable disease in Greenland as is the 
case in most of the countries in the Arctic. Hence, limited information on hepatitis 
D infection is available (11). 
A total number of 6,192 persons in Greenland have had an HBsAg blood sample 
analyzed in clinical practice in 2018 in Greenland. This represent 11% of the entire 
population in Greenland. A total of 152 were positive for HBsAg (2.5%) (data from 
correspondence with the Chief Medical Officer in Greenland). 
 It is unknown how many HBV-infected patients are followed for their infection by 
clinicians in Greenland. The municipality of “Qeqqata Kommunia” (population size 
approximately 9,400 in 2019) in the west coast of Greenland has a history of 
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following their HBV, HDV and HIV-infected patients (42). Records show that a total 
number of 480 HBV-DNA or HDV-RNA screenings or monitoring samples from 
Greenland have been analyzed in a period from 2010 to 2016 in Aalborg (data from 
supervisor Henrik Krarup [HK] in Aalborg, Denmark).  
HBV diagnostics in Greenland have changed much since 1998. During the course of 
this PhD-study enhancements in HBV blood sampling options in Greenland have 
evolved to become possible to analyze in every major city in Greenland with patients 
from villages being able to have their HBV-infection monitored without leaving for 
the Capital by airplane, but by way of boat to the nearest town. Not until 2015 could 
HBV virology blood samples be drawn on a daily basis and shipped to laboratories 
abroad in general due to uncertainty in preparation. Results on analysis are still 
within a month delay (analyzed in Aalborg, Denmark).  Results on other serological 
markers are with days of delay because of shipment of sera for analysis to Nuuk from 
any other Greenland town. Some apparatus enhancements are currently in place for 
PCR-analysis in Nuuk. This will shorten time for diagnosis and latency in eventual 
HBV-treatment. 
Serological test results are not kept in the Central laboratory data file collection for 
more than 10 years (from correspondence with Chief biomedical laboratory 
technologist in Nuuk).  Data extraction show a total number of 657 HBsAg positives 
on a period from 2007 to 2014. No earlier data on the HBV infected pregnant 
individuals or screenings on these (12,45) have been kept in Greenland and seem to 
have been lost for the moment, although data on HBV-infected individuals from 
Greenland have been cross-linked to social security numbers and death in earlier 
research done in Denmark (12). There is for that matter no follow-up on persons ever 
diagnosed with HBV through research. Although there have been intentions to 
initiate such programs, this has not been set up yet. In addition, despite that it is 
recommended there has been no official guidelines internally in Greenland for 
diagnostic work-up and follow-up, although treatment follows international and 
Danish guidelines.  
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The many different EMRs in Greenland and the limited restrictions on data 
management in every earlier EMR could bring any good purpose on elucidating 
earlier vaccination coverage, diagnosis, treatments and blood samples carried out 
on HBV-infected to a hold in even when evaluating on the smallest of settlements if 
not extremely persistent. Not to forget the unregistered newcomers or leaves with 
ever changing telephone numbers that only a very well informed and dedicated local 
health worker can grasp in settlements, while not in the urban city of Nuuk (personal 
report from KR on HBV and HDV infections in the village of Itilleq).  
Possibilities for monitoring and treatments have been substantially improved due to 
the switching of the approximately 10 different EMR platforms (‘Æskulap’-platforms) 
used nation-wide for every major city in Greenland, results from laboratory analyses 
(BCC-lab), guidelines, radiology scan images and descriptions (Infinnit) onto one 
common program platform (Cosmic) during the latest years 2014-2018 (except for 
east Greenland due to slow internet connection) (48). Moreover, telemedicine 
options have been upgraded over the decades of use (48,75,76) and more 
Greenlanders do become health care professionals. This improving access to health, 
serological-, virological-, and vaccination data on Greenlanders. Both recordings of 
vaccination and follow-up on CHB carriers may be optimised further as the mutual 
EMR (Cosmic) has been implemented more efficiently. An initial data extraction on 
a period from 2014 to 2018 in this system showed a total of 485 HBsAg positive 
samples distributed on 229 persons and with findings of 77 CHB-infected on basis of 
at least 2 positive samples drawn at least six months apart (data from Cosmic 
Information Technology-worker in Greenland). 
Nation-wide guidance on HBV and HDV-infections in Greenland has been established 
by the author of this thesis KR and supervisor HK by easily accessible guidelines 
through the Greenlandic joined EMR ‘Cosmic’ both on screening and treating 
pregnant women and monitoring known HBV and HDV-infected adult patients.  
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Other geographical barriers to HBV-monitoring are due to the fact that most 
specialized work-up and apparatus is accessible only in the capital Nuuk. This include 
magnetic resonance cholangiopancreatography (MRCP), CT scans and liver biopsies. 
Biopsies are send to Denmark for evaluation and diagnosis. Ultrasonography 
equipment is accessible in most cities although educational skill in use differ 
between towns. Only one (sometimes two) radiologist are working in Greenland and 
only in Nuuk. No hepatologist resides in Greenland. All hepatitis infected 
Greenlanders in need of diagnostic work-up are referred to the consultants at the 
Department of Internal Medicine at Queen Ingrid’s Hospital in Nuuk. 
Correspondence to specialists in Denmark on mail, regular “snail” mail or phone 
ensure updated work-up and treatment with a reliable coverage in Greenland. 
 
Nuuk, Greenland 
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CHAPTER 6. DISCUSSION 
Here the main results and methodological considerations of the three studies are 
discussed. After a brief presentation of the main results from our project, the three 
studies are discussed individually in relation to the current available literature. The 
methodological considerations are then discussed in depth and include a broad 
discussion of potential sources of bias and confounding, and with the addition of 
validity. Lastly, monitoring and containment of HBV-infections in Greenland is 
evaluated. 
KEY RESULTS 
With this project, we have documented that prevalences of serological markers of 
hepatitis B, D and C virus infection showed no difference between Greenlanders 
living in Greenland and Greenlanders who had migrated to Denmark. This imply 
infection before migration on an earlier age from a high endemic area to a low 
endemic area. Our studies did not show evidence of serological or clinical signs of 
disease when comparing HBV infected to non-infected when also considering alcohol 
consumption. Greenland Inuit had higher levels of AST, GGT and ALK than non-Inuit, 
regardless of alcohol intake. Intravenous drug use in Greenlanders do occur in 
Denmark. Survival analyses show a markedly decrease in lifespan among the HBV-
infected on a 10-year follow-up, although this could not be found to be directly 
related to HBV-infections when looking through EMRs and registries.  
STUDY 1. HEPATITIS B, D AND C ON MIGRATION. 
Disease patterns may change due to migration. Based on register studies migration 
from Greenland to Denmark associates with higher blood pressure, obesity and 
some cancer forms (77–79). Some migrate due to better treatment opportunities in 
Denmark.  
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This is the first population-based comparative epidemiological investigation of viral 
hepatitis in Inuit populations. Median age of sexual debut in our population from 
Denmark showed no difference between HBV infection groups. In keeping with 
earlier studies, time of infection could be during childhood contacts under the age 
of ten, but also vertically during childbirth and sexually in adulthood (42,43). An Inuit 
male predominance among infected has been reported in earlier studies (12,44,49) 
and also on this study population (9). A more promiscuous way of living reported 
among younger Inuit men than women in a West Greenlandic major town may be a 
factor on mechanism of HBV-infection spread (50), although prevalence of HBV-
infections in east Greenland resembles transmission rates throughout childhood 
(44,49). Distribution on markers of HBV-infection only did differ on gender with more 
men with markers of HBV-infection in both towns and not in the settlements in our 
study from Greenland. Approximately one fourth of all non-Inuit (born in low 
endemic Denmark) had markers of earlier infection with no gender differences. As 
HBV-vaccine could have been introduced to these especially while living in Denmark 
a sub analysis on Anti-HBc-total positivity on non-Inuit showed a difference in 
percentages (11% women versus 21% men) although on too few participants to 
make any further statistically supported conclusions. These results could relate to 
transmission in adulthood and therefore transmission seem possible among adults 
in Greenland in our study population. HBV-DNA was positive in 61 participants (87 
HBsAg positive) from East and West Greenland. Three (out of the six with positive 
HBsAg) in Denmark had detectable HBV-DNA and 200 copies/mL being the highest. 
Four participants were HBsAg positive in Nuuk West Greenland and only one with 
detectable HBV-DNA (500 copies/ml). The highest HBV-DNA in East Greenland was 
38 million copies/ml. Due to a small number of HBV-DNA positive in both Nuuk and 
Denmark It is uncertain whether these numbers represent differences in viral loads 
among Greenlanders in the areas investigated in general and a correlation to 
differences in age at infection. Differences in ways of spread of HBV in towns and 
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settlements may exist, although a full enlightenment on this aspect cannot be 
accounted for in this thesis. 
The difference between reported hepatitis vaccinations, reported history of clinical 
hepatitis and actual serological markers of HBV among Inuit in Denmark might partly 
be due to HAV-infections and HAV-vaccinations in this population as earlier studies 
have shown serologic evidence and historical evidence of large epidemics in 
Greenland (49). Reporting of having had hepatitis in Greenland during a time period 
in which HAV-infections had epidemic proportion support this notion. Moreover, 
participants were answering yes to earlier hepatitis in remembrance of being told of 
having had icterus while being newborn. Also, recall bias on having had any 
vaccination may count for participant answering positively to having had an hepatitis 
vaccination. 
Variations in HBV prevalence from 1.2% to 29% have been reported among 
Greenland Inuit (11) and may partly be related to differences in the way participants 
were identified and invited (1,29,45). None of the participants received antiviral 
therapy. The lack of clinical evidence of liver disease among the participants is in 
keeping with the statement in a previous publication of “a benign course of hepatitis 
B among adult Greenland Inuit irrespective of migration” (Rex et al. 2012, 699) (1).  
None of our participants had undergone treatment for HBV and none had clinical or 
para-clinical evidence of disease burden on investigation (1). 
Co-infection of HDV in addition to HBV tends to become a more severe acute 
hepatitis while superinfection of HDV infection on a CHB carrier tends to become a 
more aggressive progression to liver cirrhosis (80). The risk of introducing HDV is a 
liability to Greenlanders. A concise description of the in the circumpolar region is 
given in the following:  
“HDV infection has been reported in 4 of 245 HBsAg-positive sera from Yukon and 
Northwest Territories in western Canada…while none of 186 native Indian and Inuit 
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and nonnative in Newfoundland and Labrador… and none of 53 HBsAg-positive 
Alaskan natives had evidence of HDV infection... We found 6 anti-HDV positive in 342 
HBV exposed Greenlanders in Greenland and 1 in 136 in Denmark. This is lower than 
the previous findings of 10% and 7% in HBsAg positive in two towns in West 
Greenland” (Rex et al. 2012, 699) (1,11,15,81,82).  
HCV testing found non HCV-RNA positive. Our finding of two (1.5%) anti-HCV positive 
Greenlanders in Denmark is in concordance with results from Langer et al (29). This 
is also similar to reports of low prevalence in general of HCV in the remaining Arctic 
in the same time-period, although in urban Alaska HCV infection were more frequent  
and probably due to IDU (33,83). 
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STUDY 2. LIVER FUNCTION TESTS IN THE COHORTS 
Rapid development in Inuit societies (48) has been suggested to contribute to higher 
use of alcohol to cope with stress (84)(85–88)(89) as it has in other parts of the world 
(90)(91). Inuit in Denmark may consume more alcohol than their counterparts in 
Greenland which is plausible due to leaving Greenland with non-Inuit partners with a 
more regular alcohol use (92) and less binge drinking (88). Inuit may exaggerate 
alcohol consumption while Europeans may understate use (87). Still, underreporting 
in Greenland that did not take ethnic origin into account have been reported (93). 
Binge drinking has been a characteristic among Inuit and was accounted for in our 
analyses. Therefore, underreporting of alcohol use in our study is not to have been 
more prominent among Inuit than non-Inuit. The low number of excess drinkers in 
the older age groups included in our study may be related to a number of factors 
including high cost of alcoholic beverages in Greenland (94), a harsh environment 
that may cause even greater danger to the affected and select survivors due to high 
alcohol-related mortality rates (95) among the younger age groups (96–98). Our 
results show a higher alcohol consumption among non-Inuit with ”fewer abstainers 
and more heavy drinkers compared with Inuit” (Rex et al. 2012) and “…Higher 
income… and cultural differences… may explain this” (Rex et al. 2012) (92,99,100).  
Inuit have Asian ancestry. As differences exist in the alcohol-metabolizing enzymes 
(101) across Asian ethnicities (102) this has also been suggested in Inuit (87,102) 
although this has not been confirmed (103). AST, GGT and ALK was higher in Inuit 
who never drink alcohol (2,101,104) compared to non-Inuit and Inuit ethnicity 
modified the association between alcohol and AST (2). Ethnic differences in LFTs 
between Inuit and non-Inuit Danes may exist.  
Ongoing viral hepatitis infection and alcohol use may accelerate liver disease 
(105,106). We found no evidence of such in our study.  Moreover, alcohol 
consumption and ongoing Hepatitis C or D virus infections may influence LFTs in 
Inuit, but could not be evaluated in our studies due to no cases. In addition, more 
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markedly elevated LFTs in clinical practice on HDV-infection has been observed in 
Greenland Inuit (personal recordings by KR).  Moreover, liver cirrhosis is still rare 
among Greenlanders with HBV and HDV, although this has been confirmed on few 
occasions and with or without an association to a history of alcohol abuse (personal 
report by KR).  
No systematic active immunization against HBV had been done in our cohort of 
participants in Greenland (9). Nevertheless, we conducted additional sub analyses 
on isolated anti-HBs positive individuals on other perspectives of assessment. This 
did not change our results.  
 
Nuuk inland, Greenland 
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STUDY 3. HBV-INFECTIONS AND LONGEVITY 
In this study, we reported on both life expectancy and disease occurrence among 
those infected with HBV, compared to biochemically confirmed noninfected 
individuals. 
HBV-infected were likely to be older, Inuit and living in East Greenland, with a lower 
alcohol consumption, a more frequent use of traditional Greenlandic diet, a lower 
BMI and a daily smoking rate of 10-20 cigarettes. The median survival in the total 
surveyed cohort was 70 years (3). This is similar to the life-expectancy in Greenland 
that was reported at the time of the investigation (107). The predicted survival was 
7 years lower for the infected individuals than for the noninfected individuals. Being 
infected with HBV carried a hazard ratio of 1.6 for death. This is in contrast to our 
findings of causes of death in the registries, as these findings suggested a lack of HBV-
related deaths. As only 31% of the non-infected had died on follow up (52% for the 
infected), this leaves some uncertainty in the survival analyses extrapolating on basis 
of the known data. 
Børresen et al. reported an higher IRR on all-cause death of 1.47 (95% CI: 1.21-1.79) 
for chronically HBV-infected persons compared  to HBV-negative persons in their 
register study (12) in concordance to our findings. In our study IRR was 2.00 (95% CI: 
1.40-2.83) for all participants from Greenland and 1.52 (95% CI: 1.02-2.26) among 
east Greenlandic participants. 
Studying the EMRs over the 10-year period did not further indicate a burden of liver 
disease in this population in concordance with a number of studies that 
demonstrated a high prevalence of HBV among Greenlanders and a low disease 
burden (11). Monitoring of even inactive HBV–infected in other areas has shown to 
be of value, as the risk of death is still increased due to HCC in this patient group 
(108–110).  
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Aging carries a process of selection, and some early HBV infection outcomes may not 
be accounted for, due to the relatively advanced age of the group that was surveyed. 
The inclusion of this older age group is not likely to underestimate deaths that were 
caused by HBV infections. Two of seven registered deaths in relation to any viral 
hepatitis in the time period 1995 through 2013 were under 50 years of age according 
to the National Board of Health (37). 
The diagnoses of HBV in Greenlanders may be insufficient.  The expected low disease 
burden could result in less attention on the disease and HBV-related illnesses or 
deaths could be misclassified for similar reasons. There was no recording of HBV-
infection in any death certificate among the participants which may support this 
notion (3).  
Leaving Greenland was not recognized as censoring in this study and only a few 
participants (25 non-Inuit and 6 Inuit individuals) left Greenland during the 10-year 
follow-up period and events in this part of the cohort was also accounted for. 
Therefore, this did not influence our results or conclusions. 
The medical services differed between East and West Greenland, in regard to that 
the main hospital in Greenland (the only hospital and therefore also the only internal 
medical department) is in the capital city of Nuuk in West Greenland. This difference 
could lead to confounding results concerning death. Moreover, socioeconomic 
status differ between East Greenland Inuit and Inuit in Nuuk, and further potential 
confounding factors on all cause death included alcohol (2), smoking (111), age, 
nontraditional Greenlandic food diet, ethnic origin and gender. Our data suggested 
an increased hazard ratio on overall death in noninfected East Greenland Inuit 
individuals, compared to noninfected West Greenland Inuit individuals (HR: 1.50; 
95% CI: 0.93-2.41), although this result was not statistically significant (3).  
Earlier studies among Greenlanders suggest alcohol consumption to be associated 
with accidental or violent deaths in our study population (2) and could thereby 
represent a potential confounding factor on infection and overall death. Moreover, 
alcohol and age have been suggested as being predictors of reactivation in HBV 
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infected, inactive carriers, and they could also be predictors of HCC and cirrhosis 
among HBV infected individuals (112). HBV genotype and the male gender may also 
be predictors of reactivation from the inactive phase (109,113). However, our data 
did not support these suggestions (3). 
As described in chapter 2 the HBV subtype B5 is argued to be a more benign form of 
HBV infection. However, it associated with a higher risk of death in this cohort.  
Through the EMRs and registries we identified an individual who had died from an 
exacerbation in hepatitis B following B cell lymphoma, in relation to chemotherapy 
and without a registered HBV prophylactic treatment. He was diagnosed with HBV 
in our clinical study and was later diagnosed within a month before his death. This 
emphasizes the importance of testing for HBV-infections prior to chemotherapy 
(114) and the importance of the availability of test results from research in clinical 
practice in Greenland (3).  
 
Sisimiut, Greenland 
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METHODOLOGICAL CONSIDERATIONS 
Strengths and limitations of the studies in this project are discussed further in the 
following. Systematic error, internal and external validity of the studies is also 
discussed in detail and evaluated. 
THE CROSS-SECTIONAL DESIGNS  
As all three studies in this PhD-thesis include cross-sectional designs, attention 
should be paid to this methodology of observational studies (115). Cross-sectional 
studies are valuable in being less time-consuming, less expensive than more 
advanced studies and can produce evidence qualifying to be a step stone to further 
investigation and often form the base for cohort studies. As cross-sectional studies 
are prevalence studies where a measured exposure and outcome is assessed at a 
given point in time, these measures can only be suggestive on causality of the 
findings, due to the limitation in establishing duration of either the exposure (in this 
case HBV-infection), the outcomes (clinical or paraclinical markers of disease) or 
both. 
 Cross-sectional design were used in study 1 to evaluate prevalences of HBV, HDV 
and HCV markers on participants in both a Greenlandic and in a Danish setting, and 
evaluate associations between participant characteristics, including HBV-infection 
status, body build and liver function tests. In study 2 the cross-sectional designs from 
study 1 were the basis for further investigation of associations between liver function 
tests, alcohol intake and HBV-infection. 
THE COHORT DESIGN 
In study 3 the cross-sectional study from Greenland formed the basis of a new 
cohort. This cohort was followed prospectively for 10 years using all available EMRs 
and registries from Greenland, linking results from the clinical study to evaluate all-
cause mortality on HBV-infection status and to elucidate clinical aspects on the 
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cohort concerning hepatitis B diagnostics, cirrhosis, end stage liver disease, HCC, 
vaccinations and other liver diseases on participants up until 2008. 
In general, cohort studies can be suggestive of the ethology or prognosis of a disease 
and are incidence studies (here mainly the incidence of death related to HBV-
infection). In some aspects cohort studies can establish duration of either the 
exposure, the outcome or both, and can be used to interpret causality, although in 
our study exposure-time of HBV-infection is still uncertain while time until death was 
not.  
Register studies and EMRs survey 
In the cohort study (study 3) registers and EMR were used and have been discussed 
in short earlier, although a more detailed discussion on this matter follows. The 
method of linking social security numbers to participants was considered valid due 
to a small population.  
As all available digital registries and EMRs in Greenland from the period (1998 to 
2008) were used in the study, any of the reported frequencies of liver diseases, HBV-
centered problems in the study are considered valid and thus resemble any known 
digitally registered somatic health data on the participants. In switching from pen 
and paper records to evolving EMRs, information might get lost. Yet, non-digitalized 
medical records are not used in this project and could hereby reduce the actual 
number of recordings on HBV-centered problems and liver problems especially on 
participants who had died early on follow-up and before EMRs were thoroughly 
established in Greenland. Although, in this time-period HBV-diagnostics in 
Greenland must have been (almost) inaccessible in clinical practice and, registry of 
HBV-related problems with pen and paper is considered minimal. The EMR reported 
number of HBV-related diagnostics are considered as approximately the actual 
number of clinical findings due to the mandatory journaling /recordkeeping in 
Greenland and therefore if anything then an underreporting of findings. As described 
under the results-section HBV-diagnostics or even vaccination recordings in a clinical 
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setting seem rare in Greenland. Unfortunately, a comparison of EMR findings and 
recordings of laboratory analyses could not be directly assessed as the earliest digital 
laboratory recordings were not established until 2007. 
The data collectors in the clinical study were blinded to the HBV status of the 
participants. The data collector investigating the registries was not blinded to the 
HBV-infected, but estimated to have very little impact on the data collection, as 
similar procedures were used for all of the participants, and all of the available data 
were scrutinized for information of HBV and liver disease relevance (3). 
Registers have inherent limitations on diagnosis and on causes of death, and there 
are no statements of uncertainty in the Danish Death Registry although, diagnosis 
on biopsies from the Danish Biopsy Registry is considered as the gold standard on 
verifying diagnosis. Death registry diagnosis on HBV-infections and on HCC on 
Greenlanders is considered to be less than actual incidences, as the liver is a site of 
metastasis and because autopsies are not regularly done on Greenlanders in 
Greenland unless considered unnatural (forensic autopsies with staff coming in from 
Denmark). Moreover, although death certificates are mandatory in Denmark and 
Greenland evaluation on death causes on the certificates done at a hospital are 
usually performed by (busy) physicians on shifts, with minor prior knowledge on the 
person who had died. This leaves some uncertainty in death certificate diagnosis.  At 
least one participant in our study had a discordance with a liver biopsy verified as 
HCC and a death certificate diagnosis with lung cancer being the official death cause 
without the mentioning of liver cancer. 
 
 Qaqortoq, Greenland 
 DISCUSSION 
79 
 
Nuuk, Greenland 
SYSTEMATIC ERROR 
Selection Bias  
Selection bias involves biases arising from the procedures by which the study 
participants are selected from its source population, or select themselves by 
agreeing to participate. Thus, selection bias is the introduction of a systematic 
difference in the selection of participants from factors that influence study 
participation. Selection bias can occur if the studied population does not reflect the 
population from which it is derived from and therefore be introduced into the 
included studies if the participants differed from the non-attenders. A randomized 
selection of potential participants and a high participation rate reduces the 
introduction of selection bias. As a randomized selection was achieved in West 
Greenland this minimizes the risk of selection bias here. East Greenlandic 
participants were not randomized as all in the selected age groups were invited, but 
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as 96% of all invited East Greenlanders participated the introduction of this form of 
bias is negligible, as the cohort comprises the overall of the entire source population. 
Also, as markers of HBV might accumulate in an aging part of the population the 
selection of only elderly participants in a population might overestimate the overall 
prevalences of the whole population.  Differences in recruitment of participants 
existed between Denmark and in Greenland. As described the potential participants 
in Nuuk had initially been selected using the hospital registration system in Nuuk in 
1998 and later validated by comparing the list to the National Civil Registration 
System (NCRS).  Of the 480 persons initially selected (25% of all 1920 persons in the 
selected agegroup in Nuuk in 1998) a total of 255 persons had moved or died and 
therefore could not be contacted on the registered address and therefore found not 
eligible for the study.  In East Greenland the NCRS was used in both the settlements 
and in the town and only 9 persons out of 161 potential participants from the 
settlements and 13 out of 197 potential participants from the town were not eligible 
due to latency in reporting of death or changing of addresses. Therefore, the initial 
selection in Nuuk did pronouncedly differ from the final selection leaving some 
uncertainty to whether the selected group could differ in composition to the 
background population in Nuuk and also in HBV-infection arrangement.  Hereby, 
selection bias could have been introduced to the participants in Nuuk. Whether the 
potential selection bias here would increase or decrease the prevalence of HBV-
infected in Nuuk or the health statuses on HBV disease is uncertain when the 
knowledge on this part of the population (Greenlanders with frequent changing of 
addresses within a town, not managing to officially change addresses, leaving for 
other towns in Greenland or Denmark as an example) is also uncertain. This part of 
the population could be of opposites in matters of HBV-infection composites, 
although no proof lies on behalf of that HBV-infected in Greenland should be more 
prominent in marginalized groups or in any specified social group. The overall 
assessment is that it might not entangle with the overall findings from Greenland 
leaving little selection bias.  
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For the recruitment of participants in Denmark small differences are apparent. Only 
individuals born in Greenland with at least one parent born in Greenland were 
included and with the supplement of Greenlanders aged 40 through 49 years also 
invited. As in East Greenland everyone with the inclusion criteria were to be invited. 
The initial contact by telephone on behalf of the inclusion criteria for most 
participants in Denmark also differed from the recruitment from Greenland. 
Eligibility of the 92 subjects who did not respond in Denmark is uncertain.  Whether 
HBV or HCV status for that matter differs in this group introducing bias by invitation 
is uncertain. Marginalized Greenlandic groups in Denmark without addresses or 
telephones might have higher prevalences of viral or bacterial infections, although 
this group count for very few but visible individuals in a mostly Caucasian population. 
A greater part might not have responded due to not having any affiliations to 
Greenland neither ethnically, familiarly or in recollection of ever living there or as in 
Greenland: because of frequent migration between towns.  Bias by invitation on 
HBV-status on this behalf is therefore estimated to be small on the participants from 
Denmark.  
Other possible selection bias problematics is the time difference on which the two 
cross-sectional studies were performed, and also the age differences among 
participants.  
The age group in Denmark also included 40 to 49 year olds. There were no internal 
statistical differences on behalf of HBV-exposure, drinking habits or BMI, although 
there was on gender, when comparing two groups of age intervals 40 through 49 
and 50 through 69.  The results section primarily contain age groups 50 through 69 
for direct logical comparison when comparing Greenlanders in Denmark and in 
Greenland, although there was no statistical proof of differences if all participants 
from Denmark were included. Moreover, when comparing age in the two cross 
sectional studies the age of the youngest participant in Denmark if examined in 1998 
would have been 32 years. As age at infection might be before this age on most in 
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the Greenlandic population the inclusion of the younger age groups are not to bias 
the result on HBV-status markedly and should be comparable to the participants 
living in Greenland, although small time trends may exist in general concerning child 
delivery, kindergarden opportunities and sexual behavior (46,48,50). As described in 
the results section HBV-status on participants living in Denmark mirrored the 
participants living in Greenland. 
As described in the results section having both parents born in Greenland increased 
the risk of having had an HBV-infection among Greenlanders in Denmark. Also, only 
a selected greater group of Greenlanders migrate to Denmark. Out of 136 
participants in Denmark 25 had only one parent born in Greenland. Only three had 
a mother born outside Greenland (on the risk of vertical transmission if mother is 
infected). Of a total of 441 Inuit in Greenland, seven participants had only one parent 
born in Greenland and none had a mother born outside Greenland. A potential 
source of selection bias lies herein. This on behalf of ethnicity (on the measure of 
parents born in Greenland) and migration on HBV-infection. This could lead to a 
reduction in overall prevalences of HBV-exposure in Inuit found in Denmark in direct 
comparisons with prevalences in Inuit in Greenland due to differences in 
composition of parent’s birthplace, although this was not found in our cross-
sectional studies. This might apply if the real composition of Inuit in the age groups 
investigated in Denmark comprise of more individuals with mixed parents than 
actually investigated and thus bias our findings away from the null when comparing 
prevalences of HBV-markers between Inuit in Denmark and in Greenland. 
 
Sisimiut, Greenland 
 DISCUSSION 
83 
Information bias 
Information bias is the result of misclassification of study participants with respect 
to disease or exposure status. Thus, the concept of information bias refers to those 
people actually included in the study. The misclassification can be either non-
differential (random error) or differential (116).  
Inuit ancestry was defined in this project as of being born in Greenland and having 
had at least one parent born in Greenland. The selection (Inuit in Denmark) or 
division of participants on behalf of Inuit ancestry was primarily broad into the 
equation in a way to try and consider if a genetic aspect (particular genetic 
constitution) derived from the Neo-Eskimo (117) could explain some of the benign 
outcomes of HBV disease found in earlier studies. Participant parents born in 
Greenland were born while the country was highly secluded. A misclassification of 
Inuit ancestry is therefore evaluated to be very small, and count for one or two 
subjects (false negative) included in the study. 
All data collections were at one point in time. Reported dietary habits, smoking 
habits and alcohol use were variables used in the different studies. The questionnaire 
on these subjects were clearly defined, the same interpreter was used in Greenland 
on all participants and the questions were asked as they were written in the 
questionnaire. This minimized the risk of differences caused by translation and 
interview technics. Recall bias is a type of information bias. The intra-individual 
variability of predictors has not been taken into account in the survival analyses and 
moreover, misclassification of place of living on all participants both in villages, 
towns and cities may exist on follow up due to migration. As an example on aging, 
people may migrate to the towns from villages or move to Denmark (has been 
accounted for and discussed) for better living conditions. The migration to towns 
seem to affect very few individuals on follow up. 
HEPATITIS AMONG GREENLANDERS IN DENMARK AND IN GREENLAND, AND THE OUTCOME OF CHRONIC HBV-
INFECTION IN GREENLAND 
84 
Misclassification on alcohol intake has been discussed earlier on aspects of ethnicity. 
In addition, gender differences in reporting could exist and the reporting of alcohol 
intake could differ between Inuit in Greenland and on Inuit migrants. As all Inuit were 
born in Greenland with the same overall cultural setting, the misclassification on 
alcohol use due to migration is considered non-differential. A difference in reporting 
of alcohol between genders according to ethnicity could exist and could be 
differential (differential misclassification) and be postulated to be greater among 
non-Inuit due to cultural differences, but this will not hamper our results, as these 
problematics are not incorporated in our analyses due to stratification on gender 
(only sub analyses using men in the results section). Underreporting of alcohol use 
may differ according to alcohol intake groups, and could also be differential or non-
differential between genders and ethnic groups. Moreover, all blood samples drawn 
were immediately separated and frozen for storage and analyses were done in 
random order. Storage duration was approximately the same for all samples. 
Misclassification due reports on habits, storage time and laboratory analyses on 
blood samples are considered non-differential. 
As HBV-infection markers were only measured on one occasion on all participants, 
misclassification of chronic and acute infections could be evident, although this 
misclassification is considered to be of a very small size. Also, non-infected 
individuals could become infected or clear an infection during a course of ten years. 
Both scenarios are considered to potentially count for very few subjects and not bias 
the results markedly.  
The diagnostic classifications on HBV-exposure has been described in the methods 
section and the unorthodox assessment of earlier infection based on Anti-HBs alone 
has been discussed in earlier studies (9,118) an briefly under study 2. Sub analyses 
did not change with selecting this group as of being vaccinated against HBV-
infection. Nonetheless, study 3 shows that looking through the EMRs one participant 
was recorded as of being HBV vaccinated by 2008. This person was non-Inuit. This 
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cross-validates the assumption of no earlier vaccination among the Greenland Inuit 
in the investigated period. Thirty Inuit from Greenland and five non-Inuit were found 
isolated anti-HBs positive in our cross-sectional study in Greenland. Misclassification 
could still exist especially among the last four non-Inuit and be of minor importance. 
The validity of accuracy in the analysis of Hepatitis serology is considered very 
precise, although specific validities on this aspect is not part of the PhD-project. 
Misclassification is considered very small. 
Misclassification of ill participants with serious disease due to HBV-infection 
(compensated liver cirrhosis or HCC) into a category of healthy persons in the clinical 
studies is possible with the options used. No diagnostics on imaging or liver biopsies 
were used in the clinical studies, although these methods of diagnostics were 
incorporated into Study 3. Transient elastography has yet to be introduced in 
Greenland. As HBV-virus infections were not in focus in the clinical setting when 
going through EMRs and as same methods were used in going through all records, 
the misclassification on these aspects are evaluated to be non-differential and in any 
case bias the results towards the null. As blood samples were frozen for 
transportation analysis on alanine aminotransferase (ALT) was not carried out. Due 
to instability in results AST was used instead. As ALT is the most common liver 
enzyme used in judging eventual hepatitis B flairs it is unfortunate not to be able to 
use this parameter when other LFTs were available. Subsequent ALTs were tried 
analyzed but could not be accomplished (a personal report by SA). 
Misclassification of the causes of death in the registries was possible if the 
nondiagnosed HBV-infected individuals died of undetected, HBV-related diseases. 
This problematic is described in detail above. 
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Nuuk fjords, Greenland 
Confounding 
Confounding occurs when the exposed and non-exposed have different background 
disease risks (115,116). Confounding can be controlled for in observational studies 
by the study design in terms of restriction and/or by either stratification or 
multivariable techniques on analyses. The adjustment for potential confounders can 
be sufficient, insufficient or overestimated and may bias associations (116,119). 
Restrictions by design were the inclusion criteria with specific age groups, specific 
areas of investigation and the ability to make an informed consent. In order to 
diminish confounding stratification of data, multivariate linear and logistic regression 
models, adjusted cox and parametric survival analyses were used to test associations 
between exposures and outcomes. Specific analyses are described in detail in the 
methods section.  
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Leaving out adjustment may lead to residual confounding (120). Unmeasured 
confounding cannot be adjusted for (119) and some degree of residual confounding 
(stratification of the confounder is not fine enough or confounding exists within 
strata) is likely to persist. The categorization into alcohol group may introduce 
residual confounding. No data was generally available on physical activity, intake of 
sugars, age at first intercourse, socio-economic factors such as education level and 
employment status, which could be suggested to be confounders and effect 
modifiers on either liver biochemistry, HBV-distribution or death. Educational level 
and sexual debut was only incorporated into the study in Denmark.  
EFFECT MODIFICATION 
Effect modification means that the effect of the exposure depends on the level of 
another variable. Effect modification shows a phenomenon that may have biological, 
clinical or public health relevance (119). Assessment on this has been presented in 
the statistics section on used on multivariate analyses. On note, as no non-Inuit had 
an ongoing infection in our studies, a measure of an interaction between ethnicity 
and infection could not be assessed(also addressed earlier).  
CHANCE  
Throughout this thesis results of the investigations have been presented with focus 
mainly based on clinical concerns and knowledge, and statistical associations have 
also been discussed in this manner (71,119,121). Stronger statistical associations and 
minimizing random error could be possible with increased sample size (116) as error 
due to chance decreases as sample size increases (116). On the aspect of chance, the 
main findings have been consistent in relation to other studies made on HBV-
infected in Greenland.  
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VALIDITY 
On basis of what has been discussed in the previous sections the internal validity of 
the studies among Greenlanders in Greenland is considered very high. The internal 
validity or comparability of Inuit in Denmark and Greenland in general on infection 
status may be questioned as they differed partially on gender, age, ethnic origin and 
time of investigation. These considerations have been answered in the previous 
section and comparability is judged adequate. In addition, the gender distribution 
differences between Inuit women in Denmark and in Greenland in our studies mirror 
the male predominance among non-Inuit in Greenland as they couple on leaving 
Greenland for Denmark. 
Our definition of Inuit may not apply in future studies on younger generations. This 
due to the admixture of other ethnicities and as more ethnic Greenlanders are born 
abroad (especially in Denmark). 
With the very low prevalences of HIV, HCV, HDV and also alcohol abuse, this project 
gives an exceptional insight into the features of the HBV-mono-infections found in 
Greenland without the confounding of host characteristics. Although the sample 
sizes of the cohorts in this project are small our findings are judged applicable to the 
Greenlandic population in general in present also in extrapolating to other age 
groups. Our project could also give some insight to the course of infection among 
other Inuit and native groups in the circumpolar regions and beyond.  
 
A DISCUSSION ON MONITORING AND CONTAINING OF HBV-
INFECTIONS IN GREENLAND 
As no nationwide HBV-monitoring program exists the actual number of infected has 
not been accounted for and is therefore very uncertain. According to earlier research 
done on Greenlanders the prevalence of HBV-infected varies from 1.2 to 29% of the 
population and the actual number of HBV-infected could count for up to four 
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thousands. The actual number of HBV-patients monitored may account for a few 
percentages of the overall infected in Greenland.  
A general characteristic among Greenland Inuit has been the lack of apparent disease 
among those infected with HBV. Hence, there has been little attention to the need 
for treatment of HBV infected in Greenland.  
Even though HBV is a notifiable disease in Greenland, this is seldom done.  The 
extremely low notification of HBV by medical health workers can be based on very 
little knowledge on this mandatory setup or difficulties in time to serologic diagnostic 
test results. Difficulties in interpretation of HBV serological results for the untrained 
eye is also an option as HBV diagnostic interpretation is not a skill that is usually 
taken into account when chosen for medical work in a city with surrounding villages 
in Greenland. The main medical doctor work force in Greenland are broadly 
specialized with mostly a background in General Medicine, although a major part of 
the medical work force also contain short term Scandinavian locum tenens 
physicians and surgeons who not necessarily know about HBV-infections in 
Greenland. Also, daily disease focus is elsewhere in the broad medical departments 
where other acute illnesses way overpass focus from chronic diseases like HBV. 
Anyhow, the resolve to further diagnosing HBV status of Greenlanders is 
undoubtedly lacking and could also be an active decision from the medical clinician 
due to lack of resources and presumable low disease burden or on the thought that 
notification has already been done prior or due to unclear guidelines. A simplified 
way to register notifiable diseases may heighten compliance also taking into account 
easily accessible ways to diagnose diseases and also raise awareness of registration.  
Better education among patients and the health care personnel including public 
health care nurses (‘Sundhedsplejersker’) is essential. Also, greater public awareness 
is necessary if problems are to be solved. Very few problems in Greenland like HBV-
infections can be isolated to one specific cause only and problems HBV alike are to 
be solved differently in a diverse country as Greenland. Solving infectious disease 
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problems in Greenland generally speaking is only possible if economic and social 
issues (poverty) are also addressed (122).  
As addressed in the results section (monitoring and containment) HBsAg-positivity 
in the general population still occur. Monitoring people with an infection on which 
we have very little evidence of disease burden, could have a stigmatizing result 
especially from health personnel and others with no prior knowledge to the nature 
of HBV-infections in Greenland, yet without known benefits for the patient. A 
discussed earlier there is no evidence that the HBV-infected in general in Greenland 
should be a more resource weak or marginalized group. On this statement, people 
with HBV-infection in Greenland could also have the same basic compliance as any 
other Greenlander. Anyhow, monitoring of the HBV disease will lead to better 
understanding of the disease in Greenland, better patient effort, which again will 
lead to more economic considerations in a country with fewer resources than 
countries we compare us to (46,48). One should take into account that the number 
of HBV-infected in Greenland far exceeds the number of any other notifiable disease 
all put together. The matching of expectations on distribution of resources to a 
monitoring program of HBV-infected should also be kept in mind on implementation.  
A feasible way of monitoring (48,72) or at least diagnosing HBV in Greenland could 
be using the joint EMR making viral hepatitis B a general diagnostic option. A 
monitoring program should derive on indicators found as important in other 
monitoring programs although the monitoring platform should be a part of the joint 
EMR, otherwise the risk of not using the platform will be evident. An effort should 
be put into analysis of effectivity and feasibility on the desired monitoring program 
(48). The linkage between para-clinical evidence of a Hepatitis B infection or CHB 
should in essence be coupled to the EMR automatically without need for manual 
entry, faulty registry and unnecessary delays although, overall assessment should be 
done by specialists.  
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Also, as the turnover of medical staff is very high in Greenland leaving holes in 
continuity in also patient disease monitoring and as this does not seem to be solved 
in the near future, no doubt leaving more influence on patient inclusion in own 
treatment and monitoring is a great part of the monitoring options in the future. 
Only a few HBV-infected patients have been identified with signs of moderate 
fibrosis on liver biopsy in Greenland. These patients were treated with lamivudine 
and later with tenofovir. Only very few patients with HDV-infection have been 
treated in Greenland with interferon-alpha or pegylated interferon. This partly due 
to side effects and living in remote areas embodying the very essence of issues that 
may arise in the Greenland health care system. Also, systematic follow-up on these 
patients has not been fully undertaken yet (11). Moreover, common anti-viral drugs 
against HBV (and HCV) used in Greenland do seem to fall in price (123).  
HDV-infection continues to be a problem in Greenland as superinfection in chronic 
carriers of HBV has caused severe liver disease even in children. An outbreak of 
hepatitis D infection was reported in one settlement in West Greenland (45), but also 
sporadic cases have been identified from the remaining parts of the west coast. The 
very high number of Inuit with HBV infection in Greenland and the other Arctic 
countries poses a risk to the Inuit societies if HDV escalates the age groups with 
horizontal spread (11). 
 Threat of horizontal spread of HIV and Syphilis among sexually active younger age 
groups and also in pregnant women has shifted to become an actual problem during 
the latest years in Greenland (2017-2019). The attempt to lessen sexual transmitted 
diseases is ongoing in Greenland. Greenland reports the highest rates of infection 
with chlamydia and gonorrhea in the North American Arctic (124) . HCV has not 
reached epidemic proportions as only very few are diagnosed every year. 
Intravenous drug use is still not an issue in Greenland. HBV-transmission is 
theoretically possible due to virus in body fluids such as breastmilk (125,126), salvia 
(127), tears (128), semen (129), vaginal secretion (130) , urine (131)  or through 
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contaminated blood and products or infected needles. HBV may cause disease 
transmission from objects even if dried for a week or maybe even longer (132). HBV 
could still be an active virus though heated to 69 degrees Celsius for 10 hours (133). 
Horizontal transmission of disease is therefore an issue on household contacts, 
between children at day-care centers (134) and sexually. Vertical infections with HBV 
are mainly transmitted in uterus through the placenta from the maternal blood to 
the fetus of infected mothers although infections through vagina or oocytes is 
possible (130).  
Due to better accommodations in Nuuk compared to many other towns and villages 
in Greenland the risk of getting the virus during early childhood might be relatively 
small, although the capital is growing rapidly with migration from higher endemic 
areas of Greenland and with the undeclared nurseries, daycares and kindergartens 
evolving due to a huge demand which cannot be upheld by the municipality. 
The active HBV immunization coverage rate among newborns was only 55% and only 
38.5% had received the fourth hepatitis vaccination in Greenland in 2012.  
Fortunately, a newer study using the joint EMR: ‘Cosmic’ showed a 98.7% coverage 
on HBV-vaccinations among newborns, but only 69.8% received the fourth 
vaccination in Nuuk in 2015 through 2016, although the nationwide coverage was 
still unknown. An estimate of newborn HBV vaccinations in Nuuk in 2016 including 
children born outside Greenland showed a coverage of 94%, while it was 76% for the 
2nd vaccine (at 3 months), 75% for the 5 months vaccine (3rd vaccine offered in the 
childhood vaccination program) and 63% for the 12 months (4th) vaccine (135). This 
still gives an opportunity for HBV to spread among the youngest and adolescents 
although the childhood vaccination program undeniably leaves a huge step stone in 
containing the HBV spread. 
Combining the health care efforts in general will give a more robust handling against 
transmission of the HBV. A monitoring program both on HBV-infected and on HBV-
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vaccinations is to be simple and robust, so that a pause in the program (regionally) 
can easily be picked up and continued later. Monitoring HBV in Greenland could 
become a landmark in monitoring infectious diseases and other liver diseases in 
Greenland. Monitoring other diseases through methods alike could align and follow. 
 
Grocery shopping in Nuuk and in a settlement 
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Differences in housing conditions in Greenland 
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CHAPTER 7. PERSPECTIVE AND FUTURE STUDIES 
This project shows that HBV-infection is an important factor on survival on 
Greenlanders and that studies should aim at confirming and explaining our findings. 
Also, our project should be followed-up. The preliminary results of a 10-year follow 
up on the Greenlandic cohort is in compilation and a twenty-year follow up is on the 
way. Although both studies lie beyond this PhD-study it seems as preliminary results 
from the 10-year clinical follow up look as if disease burden is low.  
Through our studies monitoring of disease have not been directly achievable until 
now. A letter to participants with HBV-infections should be send offering them the 
possibility to be monitored as HBV-patients in clinical practice as this possibility has 
emerged in Greenland in the years after the cross-sectional study in Greenland. 
Information to health care centers in Greenland should be send (again) on the 
infected to inform them on the implementation of follow-up. This will in turn give 
better understanding of the disease, to insure treatment on indication and to reduce 
risk of cirrhosis, end stage liver disease and HCC. 
Nonetheless, follow up is required for a better understanding of the HBV infection 
among Greenlanders and studies that as an example examine vaccination serology 
in Greenlandic children on childhood vaccination would give further insight to 
containment of the infection.  
Other scientific model designs could be useful to give further insight into HBV-
infections in Greenland, but knowledge into the natural course of HBV-infections in 
Greenland should be attainable through proper monitoring in clinical practice on this 
widespread viral disease. 
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CHAPTER 8. CONCLUSIONS AND RECOMMENDATIONS 
Through the studies included in this thesis we have enlightened aspects on HBV-
disease in Greenland and among Inuit migrants in Denmark. We document that HBV-
, HDV- and HCV-infection marker proportions in Denmark Inuit mirror proportions 
reported in Greenland and imply infection on Greenland Inuit before migration on 
an earlier age from a high endemic area to a low endemic area. We find evidence in 
our study population of the possibility of HBV-infections to be transmitted in 
adulthood in addition to infection transmission earlier in life. Our study show that 
intravenous drug use can be introduced to (few) Greenlanders on migration and 
therefore this way of introducing blood borne infections to Greenland Inuit exists. 
There is no evidence of elevated LFTs in Inuit on HBV-infection in the cross-sectional 
studies presented when measuring AST, bilirubin, ALK, GGT or albumin and no 
evidence of illness on clinical assessment nor on body build parameters. This is in full 
compliance with earlier observational studies performed in Greenland. Our project 
shows that LFT values (AST, GGT and ALK) are generally on a higher level in Greenland 
Inuit than in non-Inuit regardless of alcohol intake. Moreover, the association 
between alcohol intake and AST was modified by ethnic origin with higher levels of 
AST among Inuit than on non-Inuit on the increase of alcohol use. This suggests 
ethnic differences in liver biochemistry irrespective of alcohol consumption. In 
contrast to our other findings Inuit with HBV-infection have a profound reduced 
lifespan on a 10-year follow up, although no direct relation to severe liver disease 
due to HBV-infection could be found when looking into data registries and EMRs. The 
increased mortality on HBV-infection is in concordance with earlier register studies 
performed on Greenlanders.  
In a clinical setting, matters on HBV-infections have lost their momentum in 
Greenland with the risk of undiagnosed HBV-related deaths. In no opposition to 
many other health issues, obstacles still lie ahead concerning HBV-infection in a small 
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population on a vast island with scattered cities and settlements which are only 
accessible through air or water. Education, social problems and poor 
accommodations are serious issues that are also important to look into when trying 
to eliminate the HBV-infections in Greenland. This must be considered on a public 
scale when dealing with also other infectious disease problems. The development in 
Greenland in general leaves great enhancement opportunities for also HBV-
monitoring of which some are being used. Monitoring and treatment opportunities 
for HBV-infected have substantially improved due to unifying the electronic medical 
records and guidelines, improving access to health, serological- and virological data 
on Greenlanders. The accessibility to blood sampling has also improved the HBV-
diagnostics. Extraction of data from the EMR could be a feasible way to monitor HBV-
infected in Greenland, although regional differences must apply on specific matters 
on HBV-monitoring for a more effective setup. A feasible way of getting a clinical 
database on HBV-infected Greenlanders and on status of HBV-exposure is to reach 
out centrally in Greenland and propose to get all available data on infection status. 
This by gathering information from all the different Health Centers in the towns of 
Greenland, from “Statens Serum Institute” (SSI) in Denmark, from the Aalborg 
University hospital in Denmark and, through data done on research on Greenlanders 
over the years. Management should also rely on diagnosis by a yearly extraction of 
HBV-serology from the nationwide laboratory findings (BCC-lab) combined with 
establishing a generally attainable specific HBV-diagnosis code in the joint EMR 
(Cosmic). Combining knowledge on and methods of work-up with other chronic 
disease monitoring programs such as the diabetes program in Greenland, this could 
increase patient compliance and education of patients and health workers on 
matters of HBV-infections in the different regions of Greenland. HBV-infection 
tracing should be committed to the local health workers managing sexual 
transmitted diseases, public health care nurses (‘sundhedsplejersker’) or others 
health care services that also embody vaccination strategies in the different regions 
in Greenland. The attempt to lessen sexual transmitted disease is ongoing in 
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Greenland. Horizontal spread of disease other than sexually must also still be in 
focus. Hygiene in limiting infections and high quality kindergarten accommodations 
must be emphasized. Leaving more influence on patient inclusion in own treatment 
and monitoring is a great part of the monitoring options in the future. Better 
education to patients and healthcare workers is therefore extremely important. 
Education on matters of HBV-infections should be ongoing to keep momentum. The 
way to register notifiable diseases should be clarified and simplified and educational 
tools in the Greenlandic native language and dialects (especially East Greenlandic) 
should all be accessible through the EMR for both patients and health personnel. 
Nationwide communication directly to disease-managing medical doctors in the 
capital either by phone or by interactive media will leave better opportunities for 
education and HBV-testing, vaccinations and monitoring. The very high turnover on 
medical staff in Greenland that can leave holes in continuity on patient disease 
monitoring locally may be bypassed in doing so. The group with CHB is of 
considerable size and co-infection or superinfection with HDV can turn into a general 
serious problem if horizontal spread escalates. CHB poses a risk to the society of 
Greenland. HBV-vaccines to all non-exposed Greenlanders and to immigrants and 
monitoring of the HBV-infected will be an effective way to lessen the HBV-related 
problems in the future.  
 
Sled dogs resting after a long trip, Sisimiut, Greenland
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ABSTRACT STUDY 3. 
Background Studies in Greenland have suggested a low burden of disease due to 
chronic hepatitis B virus (HBV) infection.  
Objective A 10-year follow-up on all-cause mortality. 
Design A cross-sectional population-based clinical study with the addition of a 10-
year follow-up based on all electronic medical records. 
Setting Greenland. 
Participants Adults (n=535) aged 50 through 69 years. 
Measurements Baseline data included questionnaires on lifestyle factors, blood 
samples for liver function tests, hepatitis B serology and virology, and a physical 
examination. Follow-up was based on information from all available electronic 
medical records, biopsies, blood samples and radiological descriptions.  
Results The participation rate was 95% in the clinical study. The prevalence of 
chronic HBV infection was 16%. The HBV infection status was not specified in the 
electronic medical records in the 181 who had died. The crude overall median 
survival was 70.7 years (95% CI: 69.2-72.0), with a median survival of 67.8 for HBV-
infected patients (95% CI: 65.1-69.8) and 71.7 for noninfected patients (95% CI: 69.8-
73.4). The risk ratio of infected vs. noninfected patients was 1.7 (95% CI: 1.3-2.2), 
and the adjusted Cox analysis showed a hazard ratio of 1.6 (95% CI: 1.1-2.3). The 
adjusted parametric model showed that the predicted median survival time 
difference was 6.9 years (95% CI: 6.1-7.7), and this survival time was not explained 
by HBV-related end stage diseases or hepatocellular carcinoma. 
Limitations Possible residual confounding. 
Conclusions The 10-year follow-up on our cohort did not show HBV-related illnesses 
or deaths. However, the life span was reduced by 10% in the HBV-infected 
participants. Hence, HBV infection in Greenland may not be the benign disease that 
it has been previously suggested to be. 
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